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FOR INTENSITY MODULATEDRADIOTHERAPY 
(IMRT)
Chapter 1
General introduction and outline of the thesis
  General introduction 
Currently, cancer is the leading cause of death worldwide [1]. With the increase in life 
expectancy, cancer is expected to be a predominant mortality factor for the future. 
Treatment of cancer may consist of various interventions, such as surgery, chemotherapy, 
brachytherapy and/or external beam radiotherapy, either alone but in most cases different 
modalities are combined. Approximately 50% of all cancer patients is currently treated with 
external beam radiotherapy using photons [2,3]. 
In external beam radiotherapy, a photon beam is produced by a linear accelerator 
(linac) by bombarding a material with a high atomic number with high energy electrons. 
This photon beam, typically with an energy spectrum with a nominal maximum in the range 
of 6 MeV to 25 MeV, is then directed to the treatment site, penetrating the tissue in which 
the tumour is situated. For any such a photon beam, a certain amount of dose is released 
in healthy and tumour tissue, damaging the DNA, and destroying the cell structure with cell 
death as a result. To minimize the damage to healthy tissue, a combination of photon beams 
is usually directed to the treatment site from several angles and shaped to match the 
tumour for each treatment angle using multi leaf collimators (MLC). An MLC consists of 
many collimator leafs which can be moved independently from each other. Application of 
an MLC allows, in addition to beam shaping, modulation of the intensity of the photon beam 
for each treatment angle by a composition of various shaped segments within each 
treatment beam. This advanced radiotherapy treatment technique is known as intensity 
modulated radiotherapy (IMRT). IMRT results in complex treatments containing steep dose 
gradients, intentionally on a per-beam basis also within target volumes, allowing better 
sparing of organs at risk (OAR) whilst maintaining sufficient tumour coverage and dose 
homogeneity [4–7]. 
Patients planned for external beam radiotherapy are generally subjected to extensive 
and complex preparatory procedures. It starts with an intake in which the radiation 
oncologist talks through the entire procedure and it ends with the follow up which can take 
up to the patients entire lifetime (figure 1).  
 




Flow chart of external radiotherapy treatment procedure. 
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In terms of patient safety, each process within the procedure needs to be carefully 
monitored. Therefore, many processes within the procedure have been standardised, such 
as dose prescription, commissioning of the treatment systems and assessment of quality of 
life and acute and late radiation-induced toxicities [8–12]. As complexity of the entire 
procedure is high, dose delivery errors can occur, even after extensive commissioning [13], 
emphasizing the need for treatment verification prior to the actual treatment by patient 
specific quality assurance (QA). 
 
Patient specific QA 
In patient specific QA the treatment plan is verified in terms of dose deposition, 
independent of the treatment planning system (TPS). This can be performed by dose 
calculations, direct dose measurements, or a combination of both. The accuracy and speed 
of 3 dimensional (3D) dose calculations have considerably improved over the last years as 
computational power increased. Simple pencil beam algorithms evolved into more 
sophisticated collapsed cone algorithms and Monte Carlo calculations were introduced as 
computation time decreased significantly [14–16]. But, although high precision dose 
calculation algorithms are available, dose measurements within the dose verification 
procedure are still considered necessary as only a measurement provides a full 
representation of the effect of treatment planning and treatment machine discrepancies on 
actual delivered dose. 
Dose verification based on measurements can be performed with a broad variety of 
detectors [17,18]. In the past, when linacs were introduced for external beam radiotherapy, 
mainly point measurements were performed. Simple point measurements however are 
insufficient for dose verification of complex dose depositions with high dose gradients such 
as for IMRT. This was partly overcome by the introduction of 2D dose measurements with 
radiographic films [18,19]. Film measurements allow a 2D plane to be verified. 
Unfortunately, film measurements are limited to planes and the dose evaluation is a 
cumbersome procedure reducing efficiency of the QA procedure. For a full 3D dose 
verification, 3D detectors such as gel and solid plastic dosimetry have been developed [20–
25]. These techniques allow for a full 3D dose verification but are labour intensive and 
cannot be performed in nor easily transferred to the actual patient geometry. 
To verify a dose deposition in patient geometry based on measurements using fluence 
modelling, two different approaches have been developed. The first approach compares 
the measured detector response with the expected detector response in the validation 
geometry and corrects with, thus found perturbations, the calculated dose in patient 
geometry using ray-tracing techniques [26]. The second approach uses the measured 
detector response to reconstruct the fluence with which the dose is recalculated in patient 
geometry by a dose engine [27–32]. In this approach, as an initial step an independent 
fluence model calculates the expected fluence based on a radiotherapy treatment plan (RT-
plan). This calculated fluence is used to determine the expected detector response based 
on a detector model. By comparing this calculated detector response with the measured 
detector response, the calculated fluence can then be corrected according to the 
measurement. Finally, the corrected fluence is used to recalculate the dose in a CT 
representing the patient geometry which can be compared with the prescribed dose 
distribution enabling 3D in vivo dose verification. 
The two most common detector types available and used for fluence modelling are the 
electronic portal imaging device (EPID) and 2D detector arrays composed of ionization 
chambers. The EPID detector consists of a scintillating screen that produces photons when 
hit by x-rays, followed by detection of these photons in an amorphous silicon plate. The 
emitted light can then be used to model fluence. The EPID detector was historically 
introduced as a position verification device, but extensive research has led to the 
development of sophisticated fluence modelling based on EPID dosimetry [33]. A major 
advantage of an EPID detector is the fact that it has a high resolution and is incorporated 
within the treatment machine behind the patient allowing measurement based fluence 
modelling during patient treatment. The intrinsic advantage of including patient geometry 
has a downside that differences in expected and measured detector response can originate 
from either the treatment machine, the patient geometry or both. Furthermore, as this 
technique is not yet broadly commercially available, only departments with extensive 
knowledge on EPID dosimetry can use this technique for dose verification purposes. In 
general, commercially available dose verification tools use detector arrays composed of 
diodes or ionization chambers. In comparison to EPID dosimetry, 2D detector arrays are 
commonly mounted on the linac or positioned on the treatment table without a patient in 
place which excludes the ability of fluence modelling based on actual patient treatment 
delivery [29,30,34]. Importantly, current 2D detector arrays have a limited spatial 
resolution. Nevertheless, research has shown that high resolution dose verification can be 
performed using low resolution measurements [35], and new detectors are still being 
developed allowing fluence modelling during patient treatment [36]. Even so, pre-
treatment dose verification based on 2D measurements is a cumbersome methodology as 
it is performed prior to the actual treatment and demands, the already limited, linac time. 
With the increase in the number of patients that require 3D dose verification, efficient and 
reliable pre-treatment dose verification procedures are therefore needed. 
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 An important aspect of pre-treatment dose verification is the evaluation of observed 
dose differences. From a clinical point of view, under dosage in tumour tissue should be 
prevented to maintain sufficient tumour control and over dosage should be prevented for 
both the tumour and healthy tissue to minimize health related complaints for the patient. 
Traditionally, dose differences are evaluated using percentile dose difference, and distance-
to-agreement for a 2D plane [18]. Subsequently, these were combined successfully resulting 
in the gamma evaluation [37]. The gamma evaluation showed to be a strong dose evaluation 
methodology as it allowed a fast evaluation of dose differences in both 2D and 3D [38,39]. 
Nevertheless, the gamma evaluation is difficult to interpret in terms of clinical relevance 
[40],  which is underlined by a weak correlation between dose differences and dose volume 
histograms (DVH’s) [26,41–43]. Pre-treatment dose verification based on DVH’s will result 
in a more clinical patient specific QA procedure. Clear DVH criteria are still lacking however. 
 
Aim and outline of the thesis 
The aim of this thesis was to evaluate and improve the accuracy and efficiency of high 
resolution pre-treatment 3D dose verification using low resolution detector measurements, 
and to improve the clinical interpretation of observed dose differences.  
As previously described, several techniques are available for pre-treatment dose 
verification. The technique described in this thesis is based on the combination of dose 
calculations and high resolution fluence modelling from actual measurements at the linac 
using a low resolution detector. The detector used for measurements consists of an array 
of ionisation chambers. The resolution of the detector limits the accuracy of the fluence 
reconstruction. This limitation is overcome by the introduction of a correction kernel which 
corrects the high resolution modelled fluence in case of a difference between measured 
and calculated detector response. To what extend the use of this correction kernel is 
suitable for dose verification purposes is described in chapter 2. Chapter 3 focuses on a new 
iterative reconstruction method to reconstruct individual MLC leaf positions for a better 
representation of the actual given treatment reducing the need for the correction kernel 
method, and chapter 4 evaluates the iterative reconstruction method for a high resolution 
MLC system.  
Due to inherently limited departmental resources and steady increases in the number 
of complex treatment plans, an efficient QA-procedure is needed. Furthermore, reliability 
is of the utmost importance to guarantee treatment outcome. Reliability is sustained by 
including actual fluence measurements of the linac within the QA-procedure. 
Unfortunately, this is a cumbersome approach reducing efficiency substantially. A new 
methodology to combine the reliability of measurements with the efficiency of independent 
dose calculations is described in chapter 5. 
Evaluation of pre-treatment dose verification is generally performed by a physicist 
using the gamma evaluation which lacks information on actual dose delivered to treatment 
volumes, i.e. planning targets and OAR. In case of relevant dose differences the radiation 
oncologist is consulted and an clinical meaningful interpretation from gamma evaluation to 
patient dose distribution has to be achieved. Chapter 6 describes a new approach in which 
dose is verified according to dose delivery to treatment volumes and new criteria are 
introduced which better involve the radiation oncologist in clinically more representative 
pre-treatment 3D dose verification of advanced radiotherapy treatment plans.  
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Abstract
The COMPASS system (IBA Dosimetry) is a quality assurance (QA) tool which reconstructs
3D doses inside a phantom or a patient CT. The dose is predicted according to the RT plan
with a correction derived from 2D measurements of a matrix detector. This correction
method is necessary since a direct reconstruction of the fluence with a high resolution is 
not possible because of the limited resolution of the matrix used, but it comes with a 
blurring of the dose which creates inaccuracies in the dose reconstruction. This paper
describes the method, and verifies its capability to detect errors in the positioning of a
MLC with 10 mm leaf width in a phantom geometry. Dose reconstruction was performed
for MLC position errors of various sizes at various locations for both rectangular and IMRT 
fields and compared to a reference dose. It was found that the accuracy with which an
error in MLC position is detected depends on the location of the error relative to the 
detectors in the matrix. The reconstructed dose in an individual rectangular field for leaf 
positioning errors up to 5 mm, was correct within 5% in 50% of the locations. At the
remaining locations, the reconstruction of leaf position errors larger than 3 mm can show
inaccuracies, even though these errors were detectable in the dose reconstruction. Errors
larger than 9 mm created inaccuracies up to 17% in a small area close to the penumbra. 
The QA capability of the system was tested through gamma evaluation. Our results
indicate that the mean gamma provided by the system is slightly increased and that the
number of points above gamma 1 ensures error detection for QA purposes. Overall, the
correction kernel method used by the COMPASS system is adequate to perform QA of
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Advanced radiotherapy techniques, like intensity modulated radiotherapy (IMRT) or 
arc therapy, aim at concentration of the dose inside the tumour, while sparing organs at 
risk. To achieve this, the treatment plans often have high gradient dose distributions, 
which emphasize the need of control of the beam delivery  and of the patient positioning 
[1,2]. Efforts have been made to cover both aspects, with several detectors and methods. 
The patient positioning can be verified on-line via cone-beam CT and EPID detectors, and 
fixation techniques have been improved. Control of the beam delivery is performed by 
several methods, which can be used in parallel. The output of the linear accelerator can be 
determined via point measurements, and the shape and magnitude of the delivered dose 
distribution can be verified by multi-dimensional detectors.  
The verification of both absolute and relative dose distributions to be delivered is 
traditionally performed in a phantom prior to treatment. Measurements are analyzed by 
comparing the expected with the measured dose, and a set of criteria is used to 
determine whether the plan passes or fails the verification. The criteria that can be 
applied depend on the technology used. A high resolution dose measurement is obtained 
in one or more planes with film based quality assurance (QA) procedures [3]. In contrast 
to films, 2D detector arrays of ionization chambers, diodes or scintillator detectors provide 
low spatial resolution measurements in one plane, with an output that is more reliable 
and instantly available during the QA procedure [4]. Alternatively, EPID dosimetry is 
possible, but has a limited field of view and is, by lack of commercial products, not yet 
easily implemented in a department [5]. 
Since these traditional QA procedures are done in a phantom and the criteria that can 
be used depend on limits of the applied technology, it is often difficult to quantify and 
interpret the results in terms of clinical impact for the patient. To asses this issue, Renner 
et al proposed a method to reconstruct the beam fluence and to compute 3D doses inside 
the patient CT [6]. The fluence is measured with films, and then a dose reconstruction is 
performed. With reconstructed 3D doses inside a patient CT, a direct comparison of the 
deposited dose in regions with tumour and organs-at-risk can be done, to achieve a more 
representative and complete QA at a patient level. The proposed film verification is strictly 
a dosimetric delivery check, as the measurements are performed without the patient and 
the reconstruction is done with the patient CT used for the planning. Such a method of 
fluence reconstruction can be applied to other 2D detector systems including on-line 




The COMPASS system (IBA Dosimetry) is a commercially available solution which uses 
a 2D ionization chamber matrix and is able to reconstruct 3D doses in phantom or patient 
CT. The system can be used independently from the detector: a dose calculation can be 
performed without measurement to provide an independent dose calculation. It contains 
several tools to analyse the data in patient anatomy such as dose volume histograms 
(DVHs). The motivation for our study is that these advanced possibilities require accurate 
dose reconstruction including error detection as a prerequisite. This paper focuses on QA 
of the treatment plan and the dose delivery as combined in a measurement-based 
procedure. The included dose reconstruction method is expected to suffer from the low 
spatial resolution of the ionization chamber matrix measurements (typically above 5 mm), 
in comparison to film QA or EPID dosimetry. This limited resolution can impair the 
reconstruction capability of the system, notably in case of small IMRT segments where a 
spatial frequency of at least 0.4 mm-1 would be required to represent the true dose 
distribution [9,10]. To mitigate this problem, the COMPASS system uses a model to predict 
the linac fluence, and then corrects the prediction according to the measurements 
obtained at the linac. This procedure, based on a correction kernel, allows an utilisation of 
high resolution fluence, but comes with potential inaccuracies in the dose reconstruction 
that need further analysis.  
The purpose of this paper is to evaluate the capability of the COMPASS correction 
kernel method to reconstruct 3D doses that can be used to detect delivery errors. First the 
method of reconstruction by use of a correction kernel is described. Next, the accuracy in 
detecting errors in MLC position at the edge of a single field is quantified in terms of 
remaining position errors, reconstructed dose and gamma evaluation. Finally, the 
performance of the system in IMRT QA is evaluated with a clinical IMRT field. 
 
Material and Method 
Description of the COMPASS system 
General workflow 
In the measurement-based procedure, the aim of the COMPASS system is to 
reconstruct a high resolution 3D dose from low resolution detector measurements (figure 
1). The system uses a model of the linear accelerator to generate, with a 2D high-
resolution grid (typically 2x2 mm2 per pixel), a prediction of the fluence (ψpredicted) 
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Introduction 
Advanced radiotherapy techniques, like intensity modulated radiotherapy (IMRT) or 
arc therapy, aim at concentration of the dose inside the tumour, while sparing organs at 
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according to the radiotherapy treatment plan (DICOM RT Plan). The computation of a 
detector response prediction (Rpredicted) is performed through a detector model, and this 
prediction is compared to the measured response obtained at the linac. The resulting 
difference is used to modify the predicted fluence, yielding the reconstructed fluence 
(ψreconstructed). From this reconstructed fluence, the 3D dose is reconstructed, via the dose 




The predicted detector response, computed from the predicted fluence, is compared to the measured 
response to correct the fluence and reconstruct the dose. The predicted and reconstructed fluences 
have a high spatial resolution, while the low resolution parts of the system concern the detector 
responses (predicted and measured). Symbols are explained in the text. 
 
Comparison of the predicted and measured detector response 
The fluence coming from the linac is measured with a 2D ionization chamber matrix. 
The analysis of the measurements follows a procedure similar to the one described by 
Poppe et al [4]. The measured detector response is compared to a predicted detector 
response, which is computed from the predicted fluence Ψpredicted and the detector 








),(  (1) 
fi: 2D detector response function of ionization chamber i in the MatriXX coordinate system  
 
In this paper, the MatriXX detector [12] was used in several configurations. This 
detector array is a 2D matrix of 1020 ionization chambers, with a centre-to-centre 
distance of 7.62 mm; the chambers are cylindrical cavities of 5 mm height and 4 mm 
diameter. The dosimetric properties of the MatriXX detector have been described by 
Herzen et al [13]. Notably, the instrumental response function of the detector to a 1 mm 
wide beam can be approximated by a Gaussian with 5.8 mm full width at half maximum 
(extrapolated from Herzen et al [13], figure 4).  
Fluence correction method 
The fluence correction is applied in case of discrepancies between the predicted and 
the measured detector responses. The first step of this process is to scale the predicted 
fluence to the measured output of the linac (COMPASS user guide 2.0). The predicted 
fluence is scaled according to the difference between the measured matrix response and 
the predicted matrix response (sum over the whole matrix of the ionization chamber 
responses). The second step is called “residual response correction”. This procedure 
corrects the fluence according to the response difference of the individual ionization 
chambers (formula 2) with a fluence correction kernel (formula 3). 
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The fluence correction kernel follows from the detector response function as the 





An elementary fluence in one 
element of the fluence grid 
(a) gives a response in the 
detector according to the 
detector response function f 
(b). The fluence correction 
kernel k is the theoretical 
fluence (c) that produces a 
signal in exactly one single 
ionization chamber (d). In practice, the correction kernel (c) is proportional to the difference in signal 
between the predicted and measured response. Note the negative parts in the fluence correction 
kernel that are required to cancel out responses in neighbouring ionization chambers. 
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according to the radiotherapy treatment plan (DICOM RT Plan). The computation of a
detector response prediction (Rpredicted) is performed through a detector model, and this
prediction is compared to the measured response obtained at the linac. The resulting 
difference is used to modify the predicted fluence, yielding the reconstructed fluence
(ψreconstructed). From this reconstructed fluence, the 3D dose is reconstructed, via the dose
engine based on a collapsed cone model [11], inside a phantom or a patient CT (typically
2x2x2 mm3).
Figure 1:
The predicted detector response, computed from the predicted fluence, is compared to the measured
response to correct the fluence and reconstruct the dose. The predicted and reconstructed fluences 
have a high spatial resolution, while the low resolution parts of the system concern the detector
responses (predicted and measured). Symbols are explained in the text.
Comparison of the predicted and measured detector response
The fluence coming from the linac is measured with a 2D ionization chamber matrix. 
The analysis of the measurements follows a procedure similar to the one described by
Poppe et al [4]. The measured detector response is compared to a predicted detector
response, which is computed from the predicted fluence Ψpredicted and the detector









fi: 2D detector response function of ionization chamber i in the MatriXX coordinate system
In this paper, the MatriXX detector [12] was used in several configurations. This
detector array is a 2D matrix of 1020 ionization chambers, with a centre-to-centre 
distance of 7.62 mm; the chambers are cylindrical cavities of 5 mm height and 4 mm 
diameter. The dosimetric properties of the MatriXX detector have been described by
Herzen et al [13]. Notably, the instrumental response function of the detector to a 1 mm
wide beam can be approximated by a Gaussian with 5.8 mm full width at half maximum
(extrapolated from Herzen et al [13], figure 4). 
Fluence correction method 
The fluence correction is applied in case of discrepancies between the predicted and 
the measured detector responses. The first step of this process is to scale the predicted 
fluence to the measured output of the linac (COMPASS user guide 2.0). The predicted 
fluence is scaled according to the difference between the measured matrix response and 
the predicted matrix response (sum over the whole matrix of the ionization chamber 
responses). The second step is called “residual response correction”. This procedure 
corrects the fluence according to the response difference of the individual ionization 
chambers (formula 2) with a fluence correction kernel (formula 3). 
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Ascaling: scaling factor 
NIC: number of  ionization chambers 
Ri: residual response in ionization chamber i 
ik : fluence correction kernel of ionization chamber i 
The fluence correction kernel follows from the detector response function as the 
theoretical fluence which would produce a response in a single ionization chamber (Ri) 
(figure 2). 
Figure 2: 
An elementary fluence in one 
element of the fluence grid 
(a) gives a response in the 
detector according to the
detector response function f
(b). The fluence correction
kernel k is the theoretical 
fluence (c) that produces a
signal in exactly one single 
ionization chamber (d). In practice, the correction kernel (c) is proportional to the difference in signal 
between the predicted and measured response. Note the negative parts in the fluence correction 
kernel that are required to cancel out responses in neighbouring ionization chambers. 
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Experimental determination of the fluence correction 
kernel 
The fluence correction kernel was obtained experimentally by providing the COMPASS 
system artificial measurements in a single ionization chamber. The rest of the ionization 
chambers were set to a background value to prevent truncation of negative numbers. The 
fluence and the dose were reconstructed by the COMPASS system with a plan showing a 
closed MLC, to invoke the correction kernel on the unexpected signal. The dose coming 
from the background was then subtracted. The fluence was exported from a research 
version of the system (RaySearch laboratories).  
An important parameter while considering the shape of the correction kernel is the 
effective associated detector resolution, which is determined by the physical distance 
(7.62 mm) between detectors in the MatriXX and the linac source to detector distance 
(SDD). A larger SDD results in a higher effective resolution but a smaller field of view. The 
vendor recommends an SDD such that one row is aligned with one MLC leaf pair. To 
investigate effects of a possible increase of the projected resolution, the detector was 
used in two configurations, described in the experimental configuration.  
 
Effect of the correction kernel 
The capability to detect leaf positioning errors is essential in IMRT QA, since a small 
position discrepancy can induce large output differences [14,15]. The correction kernel 
plays for this purpose a fundamental role, as the detected errors will be reconstructed by 
the correction kernel. The effect of the kernel was investigated by intentionally 
introducing errors in the position of the edge of a rectangular field. Since the correction 
kernels are applied in a fixed position bound to the detector device, its effect depends on 
the position of the MLC leaves with respect to the ionization chambers of the matrix. The 
overall effect was assessed by applying an error of a given size at various locations in the 
field: for every error size investigated (from 1 to 20 mm), at least 10 locations were used 
with steps of 1 mm.  
Figure 3 shows typical profiles of an intentionally introduced 5 mm error. The planned 
dose and the delivered dose were obtained from the COMPASS system, without correction 
kernel. An error was deliberately introduced in the delivered dose. The reconstructed dose 
was the dose obtained from the system in case of disagreement between the plan and the 
delivery: the prediction (similar to the planned dose) is corrected by the correction kernel 
according to the real delivery (similar to the delivered dose). A comparison between the 
delivered dose and the reconstructed dose was performed. The penumbra of the 
reconstructed dose is analysed with a home-made Matlab program, to determine the 
error position of the 50% dose, the maximum dose error, and to perform a gamma 
evaluation [16]. The gamma index was obtained with 1 mm interpolation, and two 
parameters were chosen as clinically used in our department: the mean gamma value and 


















Clinical IMRT field 
In a clinical IMRT plan, multiple adjacent and overlapping field segments are created 
for one beam, and several beam directions are used. If a minor calibration error in one 
leaf pair occurs, every segment will show the error, but the overall effect of this error will 
be integrated over the different fields and segments. To validate the capability of the 
COMPASS system to perform accurate QA of such plans, a typical head–and-neck patient 
plan was used. Results will be shown for one of the 7 beams, which includes 12 segments. 
Position errors were introduced for 5 leafs, sufficiently separated to be considered as 
independent effects. Those 5 leaves were retracted from 1 to 10 mm. Analysis of this plan 
was performed according to our standard, by using an adapted version of Doselab 
(http://doselab.sourceforge.net). A gamma analysis with 3%/3 mm criterion was 
performed. This plan was also measured with EBT2 films, for an intentionally introduced 
error of 5 mm, the plans with and without the introduced error were irradiated and 
measured. The measurements were then subtracted.  
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Figure 3: 
Planned, delivered and 
reconstructed dose profiles in 
case of an intentionally 
introduced 5 mm error in the 
field edge position (relative to 
the planned position). The 
reconstructed dose is a typical 
dose that can be obtained with 
the COMPASS system in case of 
an error in leaf positioning. The 
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Measurements were done with an Elekta linac equipped with an MLC with 10 mm leaf 
width. A 6 MV beam was delivered with gantry angle 0º. The MatriXX Evolution detector 
was used with 20 mm solid water build up, in two configurations: 
- SDD=762 mm: short holder configuration. In that situation the rows and the MLC 
leaf pairs are aligned. 
- SDD=1000 mm: long holder configuration. In that situation the detector is at the 
isocenter: the distance between detector elements is 7.62 mm, and the detector 
rows and the leaf pairs are not aligned. 
 
The dose was reconstructed by the COMPASS system in a 300x300x500 mm3 solid 
water phantom. Analysis was performed at 12 mm depth. The dose grid had a 2x2x2 mm3 
resolution, interpolated to 1x1x1 mm3 for analysis. 
The irradiated films, used for the IMRT field, were radiochromic films (Gafchromic 
EBT2, ISP Corp.), positioned in coronal orientation in the middle of a 300×300×500 mm3 
solid water phantom. The day after irradiation the films were scanned on a commercial 
flatbed scanner (V700, Epson), followed by conversion of optical density to dose. The 
conversion method was corrected for non-uniformity artefacts intrinsic in flatbed film 
scanners as described in recent publications [17,18]. The film inhomogeneities were 
corrected by a double exposure procedure [19]. 
 
Results 
Description of the fluence correction kernel 
The fluence correction kernel profile, used by the COMPASS system, is given in figure 
4. The profile runs over the central horizontal axis of the 2D correction kernel that is 
indicated in the insert. The peak value was proportional to the difference between the 
predicted detector response and the measured one. The reconstructed dose profile of the 
residual response of one ionization chamber is also provided for comparison. The 
deposited dose at 12 mm depth corresponds to a slight blurring by convolution of the 
photon fluence. 
 
   
 
The shape of this fluence profile had a full width at half maximum of 7.0 mm. The 2D 
fluence reconstructed by the correction kernel of one ionization chamber showed 4 
negative parts, distributed on both sides of the peak along the vertical and horizontal 
directions. Those negative parts describe the positions of the 4 adjacent ionization 
chambers, and their amplitude is -10% of the maximum value.  
 
Effect of the correction kernel 
Dose reconstruction 
The accuracy of the reconstructed dose depended on where the error was localised 
on the 2D array. If a leaf tip was located at the projected centre of one ionization 
chamber, and if this leaf was erroneously retracted, it resulted in a too high dose that was 
reconstructed at the position of the ionization chamber, created by the superposition of 
the planned dose and the correction kernel of the ionization chamber. In that situation, 
the position of the 50% dose was inaccurately reconstructed, as is illustrated in fig. 3. If 
the leaf was pushed in the field, opposite errors in the reconstruction could be observed. 
However in case the leaf tip was in between two ionization chambers, no error in the 
reconstruction was made. 
The error in the position of the 50% dose in comparison to the planned position and 
the error in the maximum dose were recorded in different positions of the field edge, for 
error sizes from 1 to 20 mm. The position of the field edge was moved every mm in order 
to obtain every possible configuration of the penumbra position with respect to the 














Experimental profile of the 
fluence correction kernel 
(photons), and its 
corresponding reconstructed 
dose profile at 12 mm depth in 
a water phantom (2x2 mm2 
grids). Both results were 
normalised to their maximal 
value (100%). Top-right: 2D 
shape of the correction kernel. 








Measurements were done with an Elekta linac equipped with an MLC with 10 mm leaf 
width. A 6 MV beam was delivered with gantry angle 0º. The MatriXX Evolution detector 
was used with 20 mm solid water build up, in two configurations: 
- SDD=762 mm: short holder configuration. In that situation the rows and the MLC 
leaf pairs are aligned. 
- SDD=1000 mm: long holder configuration. In that situation the detector is at the 
isocenter: the distance between detector elements is 7.62 mm, and the detector 
rows and the leaf pairs are not aligned. 
 
The dose was reconstructed by the COMPASS system in a 300x300x500 mm3 solid 
water phantom. Analysis was performed at 12 mm depth. The dose grid had a 2x2x2 mm3 
resolution, interpolated to 1x1x1 mm3 for analysis. 
The irradiated films, used for the IMRT field, were radiochromic films (Gafchromic 
EBT2, ISP Corp.), positioned in coronal orientation in the middle of a 300×300×500 mm3 
solid water phantom. The day after irradiation the films were scanned on a commercial 
flatbed scanner (V700, Epson), followed by conversion of optical density to dose. The 
conversion method was corrected for non-uniformity artefacts intrinsic in flatbed film 
scanners as described in recent publications [17,18]. The film inhomogeneities were 
corrected by a double exposure procedure [19]. 
 
Results 
Description of the fluence correction kernel 
The fluence correction kernel profile, used by the COMPASS system, is given in figure 
4. The profile runs over the central horizontal axis of the 2D correction kernel that is 
indicated in the insert. The peak value was proportional to the difference between the 
predicted detector response and the measured one. The reconstructed dose profile of the 
residual response of one ionization chamber is also provided for comparison. The 
deposited dose at 12 mm depth corresponds to a slight blurring by convolution of the 
photon fluence. 
 
   
 
The shape of this fluence profile had a full width at half maximum of 7.0 mm. The 2D 
fluence reconstructed by the correction kernel of one ionization chamber showed 4 
negative parts, distributed on both sides of the peak along the vertical and horizontal 
directions. Those negative parts describe the positions of the 4 adjacent ionization 
chambers, and their amplitude is -10% of the maximum value.  
 
Effect of the correction kernel 
Dose reconstruction 
The accuracy of the reconstructed dose depended on where the error was localised 
on the 2D array. If a leaf tip was located at the projected centre of one ionization 
chamber, and if this leaf was erroneously retracted, it resulted in a too high dose that was 
reconstructed at the position of the ionization chamber, created by the superposition of 
the planned dose and the correction kernel of the ionization chamber. In that situation, 
the position of the 50% dose was inaccurately reconstructed, as is illustrated in fig. 3. If 
the leaf was pushed in the field, opposite errors in the reconstruction could be observed. 
However in case the leaf tip was in between two ionization chambers, no error in the 
reconstruction was made. 
The error in the position of the 50% dose in comparison to the planned position and 
the error in the maximum dose were recorded in different positions of the field edge, for 
error sizes from 1 to 20 mm. The position of the field edge was moved every mm in order 
to obtain every possible configuration of the penumbra position with respect to the 














Experimental profile of the 
fluence correction kernel 
(photons), and its 
corresponding reconstructed 
dose profile at 12 mm depth in 
a water phantom (2x2 mm2 
grids). Both results were 
normalised to their maximal 
value (100%). Top-right: 2D 
shape of the correction kernel. 







SDD of 762 mm. Because of the effective detector distance of 10 mm the pattern shows a 
repetition at 10 mm.  
- for 50% of the locations (see figure 5, locations 1, 2, 3, 9 and 10), the COMPASS 
dose reconstruction had a limited artefact (<5% and <2 mm in the dose 
reconstruction), 
- for the other 50% locations (positions 4 to 8), the artefact created local dose 
inaccuracies from 5% to 11%, while the error in position of the 50% dose stayed 
within 2 mm. 
 
Whatever the error size, the inaccuracy in the field edge position was always smaller 
than 2.5 mm. The artefact in the maximum dose reconstruction increased according to the 
size of the leaf position error. Up to 3 mm error, the artefact in the reconstructed dose 
was smaller than 5%. The maximum inaccuracy due to COMPASS artefact was found for 9 
mm error, where the maximum dose inaccuracy was 17%. For errors larger than 9 mm (10 




for a 5 mm field edge 
position error as a 
function of the 
location of the field 
edge. The dose 
blurring at the edge 
of the field is 
responsible for errors 
in the maximum dose 
up to 11.3% (top), 
and errors in the 
position of the 50% 
dose (bottom). Every point represents one location of the field edge, with 1 mm shift between two 
adjacent locations. The SDD is 762 mm. 
 
Effect on the gamma evaluation 
Gamma evaluation of the previous experiments was performed in a plan at 12 mm 
depth, to verify the QA capability of the system. Figures 6 and 7 summarise the results. 
The REFERENCE curves represent the difference between the delivered dose and the 



















   

















Gamma evaluation of edge positioning errors 
reconstructed by the COMPASS system, for several sizes 
of the introduced error. The curves show the relative 
number of points above gamma=1. Every point 
represents the average over 10 successive locations of the 















planned dose, while the 
COMPASS curves 
correspond to the difference 
between the reconstructed 
dose and the planned dose. 
Every point represents the 
average over 10 successive 
locations of the field edge. 
The COMPASS 
reconstruction algorithm 
overestimated the mean 
gamma value, obtained for 
several error sizes, from 2% 
to 8% (figure 6). Despite the 
variability of the result 
values obtained for the 10 
field edge locations, the 
mean gamma value was 
proportional to the 
introduced error size, and a 
difference in error size could 
be shown by the mean 
gamma. The standard 
deviations between the 10 
locations for one specific 
error size, were in the order 
of the COMPASS curve 
proportionality coefficient 
(0.032 mean gamma error 
per mm edge error for 
gamma 3%/3 mm, and 0.019 
for gamma 5%/5 mm). These 
standard deviations can be 
explained by the gamma 
algorithm which uses a 












Mean gamma evaluation of edge positioning errors 
reconstructed by the COMPASS system, for several sizes of 
the introduced error. Every point represents the average 




SDD of 762 mm. Because of the effective detector distance of 10 mm the pattern shows a
repetition at 10 mm.
- for 50% of the locations (see figure 5, locations 1, 2, 3, 9 and 10), the COMPASS
dose reconstruction had a limited artefact (<5% and <2 mm in the dose 
reconstruction),
- for the other 50% locations (positions 4 to 8), the artefact created local dose
inaccuracies from 5% to 11%, while the error in position of the 50% dose stayed
within 2 mm.
Whatever the error size, the inaccuracy in the field edge position was always smaller
than 2.5 mm. The artefact in the maximum dose reconstruction increased according to the
size of the leaf position error. Up to 3 mm error, the artefact in the reconstructed dose
was smaller than 5%. The maximum inaccuracy due to COMPASS artefact was found for 9
mm error, where the maximum dose inaccuracy was 17%. For errors larger than 9 mm (10
to 20 mm), the reconstructed dose showed the same inaccuracy values as for 9 mm error.
Figure 5:
Dose reconstruction
for a 5 mm field edge
position error as a
function of the
location of the field
edge. The dose
blurring at the edge
of the field is
responsible for errors
in the maximum dose
up to 11.3% (top),
and errors in the
position of the 50%
dose (bottom). Every point represents one location of the field edge, with 1 mm shift between two
adjacent locations. The SDD is 762 mm.
Effect on the gamma evaluation
Gamma evaluation of the previous experiments was performed in a plan at 12 mm
depth, to verify the QA capability of the system. Figures 6 and 7 summarise the results. 
The REFERENCE curves represent the difference between the delivered dose and the 


































Gamma evaluation of edge positioning errors 
reconstructed by the COMPASS system, for several sizes 
of the introduced error. The curves show the relative 
number of points above gamma=1. Every point 
represents the average over 10 successive locations of the 
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Mean gamma evaluation of edge positioning errors 
reconstructed by the COMPASS system, for several sizes of 
the introduced error. Every point represents the average 
over 10 successive locations of the field edge. The SDD is 
762 mm. 
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Concerning the number of points above gamma=1, the number of points that fail the 
evaluation was higher with the COMPASS reconstruction algorithm (figure 7) than the 
REFERENCE values. The standard deviations of these values were smaller than 1%. One 
can notice also that, as expected for a gamma 5%/5 mm evaluation, going from a 4 mm 
error to a 5 mm error increases significantly the number of points above gamma 1 (+ 
2.2%) in the REFERENCE curve, which is not the case with the COMPASS reconstruction 
method. 
Overall, the effects of the inaccuracies in the dose reconstruction did not seem to 
compromise the COMPASS capability to detect an error in the delivery, as the mean 
gamma of the evaluated plan was always slightly increased by the correction kernel 
method. The increase in the number of points above gamma=1 still ensures a good error 
detection of MLC leaves with the COMPASS system. 
 
Clinical IMRT field 
To validate our results, a clinical case of one beam from a head-and-neck patient was 
used, with introduced errors from 1 to 10 mm. The results represent the superposition 
effect of several segments, for which the introduced errors occurred each time in the 




Dose difference (%, 
relative to the prescribed 
dose) of a beam (12 
segments) in the H&N 
plan, for 5 leafs with 5 
mm introduced errors. 
COMPASS dose difference 
agreed with the film but 
shows more blurring. A film to film registration error of the order of 0.5mm introduced dose 
differences in the high gradient regions (field edges). The SDD is 1000 mm. 
 
Figure 9 describes gamma evaluation results with a 3%/3 mm criterion, with a 
recommended position of the matrix where the rows were aligned with the leaf pairs. The 
correction kernel had a small impact on the gamma values. The mean gamma value and 
the number of points above gamma=1 of the correction kernel method were sufficiently 
accurate to warrant detection of errors in MLC leaf positions. 
Figure 9: 
Mean gamma and number of points above gamma 1 (3%/3 
mm) of several errors in 5 leaf pairs of the H&N case. The 
SDD is 762 mm. 
 
Figure 10: 
Mean gamma and number of points above (3%/3 mm) of 
several errors in 5 leaf pairs of the H&N case. The SDD is 
1000 mm. 
 
A similar evaluation was 
performed with the matrix at 
the isocentre (figure 10). In 
this situation, the correction 
kernel was smaller, but a 
systematic blurring of the 
errors is done for the leaf 
pairs which are positioned 
between two detector rows 
of the matrix (see figure 8, 
the leaf pair in the top of the 
figure). The error made by 
the COMPASS reconstruction 
kernel was increased: the 
mean gamma value was 
overestimated, and the 
number of points above 
gamma=1 was decreased. 
These results are the 
consequences of the extra 
blurring of the dose in the 
vertical direction, which 
increases the error in 
distance and the mean 
gamma, and decreases the 
high gamma values of the 
plan, described by the 
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Mean gamma and number of points above gamma 1 (3%/3 
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SDD is 762 mm. 
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several errors in 5 leaf pairs of the H&N case. The SDD is 
1000 mm. 
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2D detectors arrays are very effective tools in radiotherapy. They can be used to 
perform accurate QA of IMRT fields despite their low resolution [4,9], and they allow a 
gain in time in comparison to other methods such as film dosimetry. The main 
disadvantage, their low spatial resolution, is a technological issue with on-going 
improvements, and can be compensated by several methods, such as shifting the whole 
detector [9], or by using a holder at a longer distance. A comparison of the measured 
detector response and the predicted response is possible for every individual ionization 
chamber [4], with criteria set to determine whether a plan is correctly irradiated. This 
procedure gives a good indication of the plan quality, and can be performed with several 
detectors by knowing their response function. Concerning the MatriXX detector, this 
predicted/measured response analysis can be done directly via the COMPASS system, 
which provides such analysis. Nevertheless, this procedure is limited to a detector 
response comparison, and does not quantify the effect of possible delivery errors in terms 
of deposited dose inside the patient. The COMPASS system proposes a complementary 
approach which aims to reconstruct a 3D dose in a patient geometry by using the 
measurement information, a beam model and the treatment plan. This method allows a 
better understanding of the QA results, and can lead to a more robust and also more 
intuitive QA at a patient level, as described by several authors who used other systems of 
detection [6,7]. Such a procedure using a 2D detector array has clear advantages, but also 
presents drawbacks, at least at the current level of detector technology. 
The major drawback of fluence reconstruction by using film measurements, is the 
necessity to do a time-consuming measurement per beam. Also, the measurement is 
relative, and such a method cannot provide information during the course of an 
irradiation. In comparison, a 2D detector array is able to monitor the irradiation during the 
delivery, and the analysis of the results is more straightforward. Such a procedure is more 
flexible and easier to integrate in a clinical routine. This procedure is comparable to EPID 
dosimetry, but its implementation is easier. Nevertheless, the limited resolution of current 
2D arrays decreases the quality of the reconstruction. The method proposed inside the 
COMPASS system mitigates the low resolution effects but the implemented correction 
kernel comes with an artefact that leads to several inaccuracies. The first inaccuracy 
concerns the location dependency of the reconstruction. For IMRT fields with several 
segments, this effect is integrated and its impact is small for the quantification of an error, 
as seen in the clinical case of this paper. The second inaccuracy is due to the size of the 
correction kernel. It can create inaccuracies near field edges of individual IMRT segments. 
 
 
 This artefact can be misleading for the QA output, as the maximum dose in the hot area 
can be overestimated. It can also be expected that analysis with DVHs will suffer from this 
effect. A further study needs to be performed, which is beyond the scope of this paper. 
In terms of QA capability, our results indicate that the correction kernel method 
allows an accurate determination of the mean gamma of evaluated plans. This aspect is 
fundamental to ensure good error detection with the system: the differences found on the 
number of points above gamma 1 suggest that COMPASS evaluation still ensures 
detection of MLC positioning errors via a gamma evaluation. At a large SDD, despite a 
smaller correction kernel, the misalignment of the leaf pairs and the matrix row reduces 
the gamma evaluation accuracy of the system. A configuration for which one row is 
aligned with one leaf pair has been found more reliable than a configuration that 
optimises the projected resolution. 
An advantage of the COMPASS method is the possibility to use it with other detectors 
and irradiation techniques. Two detectors are at the moment available to perform the 
measurements and apply kernel corrections; the MatriXX detector [12] and the 
transmission detector, dedicated to on-line measurements [20]. The correction kernel 
method would also be usable with future detectors with potentially higher spatial 
resolution, which should decrease the size of the correction kernel. Also, 2D detector 
arrays seem ideal to monitor complex dynamic treatments plan such as arc therapy [21], 
due to the time resolved character of the measurements. 
Overall, the effect of the correction kernel does not jeopardize the QA capability of 
the system, but one has to keep in mind that an artefact can occur at the edge of a 
treatment field. Errors in the beam delivery are detected by the system, and its location 
can be visualized in 3D. This information is expected to be usable by the physicist and the 
physician to determine whether the plan is acceptable or not, knowing that the 
localisation of the error is accurate within a few mm. Note that this paper focused only on 
inaccuracies introduced by the implemented correction kernel method in case of MLC leaf 
position errors by comparison of reconstructed dose with and without correction. This 
way, inaccuracies in the reconstructed dose without correction, e.g. caused by the fluence 
model, detector model and dose engine, were excluded from the investigation. 
Furthermore, detection of linac output errors were excluded, as this is directly linked to 
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The COMPASS dose reconstruction method uses a high resolution fluence map to 
compute 3D doses. If the delivered and the planned irradiation are similar, this offers a 
high resolution dose prediction. In case of errors during the beam delivery, the predicted 
fluence is corrected, and this correction can cause a blurring artefact of the dose. 
Nevertheless, the system is still able to accurately reconstruct the position of field edges 
with a maximum error of 2.5 mm. Also, inaccuracies in the reconstructed dose error can 
occur, up to 17% for large delivery errors, in small areas near the field edge, due to 
displacement of the dose during the reconstruction. In terms of plan evaluations, the 
mean gamma value is slightly overestimated by the COMPASS system. Furthermore, the 
number of points above gamma 1 is sufficiently accurate to ensure error detection. The 
correction kernel method used by the COMPASS system is thus suitable to perform QA of 
IMRT treatment plans. The correction kernel method is not bound to the particular 
detector or technique used in this study and may be applied to other detectors or 
situations. 
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compute 3D doses. If the delivered and the planned irradiation are similar, this offers a 
high resolution dose prediction. In case of errors during the beam delivery, the predicted
fluence is corrected, and this correction can cause a blurring artefact of the dose.
Nevertheless, the system is still able to accurately reconstruct the position of field edges
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number of points above gamma 1 is sufficiently accurate to ensure error detection. The 
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Abstract
The objective of this study was to introduce a new iterative method to reconstruct multi
leaf collimator (MLC) positions based on low resolution ionization detector array
measurements and to evaluate its error detection performance. The iterative
reconstruction method consists of a fluence model, a detector model and an optimizer.
Expected detector response was calculated using a radiotherapy treatment plan in
combination with the fluence model and detector model. MLC leaf positions were
reconstructed by minimizing differences between expected and measured detector
response. The iterative reconstruction method was evaluated for an Elekta SLi with 10.0
mm MLC leafs in combination with the COMPASS system and the MatriXX Evolution (IBA
Dosimetry) detector with a spacing of 7.62 mm. The detector was positioned in such a way
that each leaf pair of the MLC was aligned with one row of ionization chambers. Known leaf 
displacements were introduced in various field geometries ranging from -10.0 mm to 10.0 
mm. Error detection performance was tested for MLC leaf position dependency relative to
the detector position, gantry angle dependency, monitor unit dependency, and for ten
clinical IMRT treatment beams. For one clinical head and neck IMRT treatment beam,
influence of the iterative reconstruction method on existing 3D dose reconstruction
artifacts was evaluated. The described iterative reconstruction method was capable of
individual MLC leaf position reconstruction with millimeter accuracy, independent of the
relative detector position within the range of clinically applied monitor units for IMRT. Dose
reconstruction artifacts in a clinical IMRT treatment beam were considerably reduced as
compared to the current dose verification procedure. The iterative reconstruction method
allows high accuracy 3D dose verification by including actual MLC leaf positions 
reconstructed from low resolution 2D measurements.
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Abstract 
The objective of this study was to introduce a new iterative method to reconstruct multi 
leaf collimator (MLC) positions based on low resolution ionization detector array 
measurements and to evaluate its error detection performance. The iterative 
reconstruction method consists of a fluence model, a detector model and an optimizer. 
Expected detector response was calculated using a radiotherapy treatment plan in 
combination with the fluence model and detector model. MLC leaf positions were 
reconstructed by minimizing differences between expected and measured detector 
response. The iterative reconstruction method was evaluated for an Elekta SLi with 10.0 
mm MLC leafs in combination with the COMPASS system and the MatriXX Evolution (IBA 
Dosimetry) detector with a spacing of 7.62 mm. The detector was positioned in such a way 
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displacements were introduced in various field geometries ranging from -10.0 mm to 10.0 
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the detector position, gantry angle dependency, monitor unit  dependency, and for ten
clinical IMRT treatment beams. For one clinical head and neck IMRT treatment beam,
influence of the iterative reconstruction method on existing 3D dose reconstruction
artifacts was evaluated. The described iterative reconstruction method was capable of
individual MLC leaf position reconstruction with millimeter accuracy, independent of the
relative detector position within the range of clinically applied monitor units for IMRT. Dose
reconstruction artifacts in a clinical IMRT treatment beam were considerably reduced as
compared to the current dose verification procedure. The iterative reconstruction method
allows high accuracy 3D dose verification by including actual MLC leaf positions





Advanced radiotherapy treatment modalities such as Intensity Modulated 
Radiotherapy (IMRT) and Volumetric Modulated Arc Therapy (VMAT) allow to generate 
steep 3D dose gradients by complex treatment plans that consist of many segments. The 
delivery of these steep dose gradients need to be carefully monitored to guarantee patient 
safety [1]. Various 3D dose verification methods have been described in literature based on 
independent dose calculations [2,3] or dose reconstruction by incorporating 2D 
measurements which enables the inclusion of actual linac output during dose verification 
[4–7]. 
A drawback of 2D detector array measurements is the spatial resolution which is limited 
by the size of a single elementary detector and the center-to-center distance between 
detectors. In particular detector arrays composed of ionization chambers have a limited 
resolution due to the relatively large detector spacing. Poppe et.al. showed that according 
to the Nyquist sampling theorem, IMRT dose reconstruction requires a detector with a 
spatial frequency of 0.4 mm-1 which is higher than commonly available [8]. Prior knowledge 
can help to overcome this limitation, e.g. by use of a lower resolution measurement as a 
correction to a high resolution calculation. An example is the COMPASS system (IBA 
Dosimetry) which reconstructs 3D dose in a patient CT based on 2D measurements obtained 
with a low resolution ionization chamber array (MatriXX, IBA Dosimetry). Differences 
between expected fluence and measured fluence due to incorrect multi leaf collimator 
(MLC) positioning are accounted for by a correction kernel method [9].  
In a previous study, we showed the limitations of the MatriXX detector in combination 
with the COMPASS system to accurately reconstruct delivered dose in case of MLC leaf 
positioning errors [10]. The local dose reconstruction inaccuracies of the correction kernel 
method are expected to become more limiting artifacts as dose verification to patient 
specific structures becomes increasingly important [11,12]. In this study, a new iterative 
method to reconstruct actual leaf positions from low resolution 2D measurements was 
introduced. The method uses as prior knowledge the fact that energy fluence generated 
from a treatment head is dependent on a limited set of parameters. Thus, although the 
information density from 2D measurements is low, our hypothesis is that it is sufficient to 
determine multiple parameters affecting the energy fluence such as penumbra shape, jaw 
and MLC settings. The objective of this study was to introduce the iterative reconstruction 
method and to evaluate its error detection performance in reconstructing actual leaf 




Material and method 
Iterative reconstruction method 
The iterative reconstruction method used for MLC leaf position reconstruction was 
implemented using Matlab (version R2014a). It consists of a fluence model, a detector 
model and an optimizer that minimizes differences between measured and modeled 
detector response by adjusting fluence model optimization parameters independent of the 
treatment planning system (figure 1). In terms of dose verification, MLC leaf positions were 
reconstructed and adjusted in the original RT-plan. The adjusted RT-plan and measured 
detector response was then used in combination with the COMPASS system (v2.0) and the 
planning CT for 3D dose reconstruction. 
 
 
Figure 1:  
Reconstruction of MLC positions by an iterative reconstruction method and 2D detector 
measurements. The initial fluence (Ψmodel) is based on the original treatment plan (RT-plan) from the 
treatment planning system (TPS). Subsequently, from the fluence model and the detector model, the 
detector response (Rmodel) is determined. Differences in calculated detector response and measured 
detector response (Rmeas) were minimized by adjusting fluence model optimization parameters. For 
MLC position reconstruction, only a selection of source parameters and MLC leaf positions were 
optimized. Reconstructed MLC leaf positions were implemented in the original treatment plan (RT-
plan*) for a better representation of the actual given treatment plan which was eventually used in 
combination with the measured detector response for 3D dose reconstruction. 
 
Fluence model  
The fluence generated by the linac head was modeled with an RT-plan and the fluence 
model with fluence model parameters that comprised of source parameters, jaw settings 




















Advanced radiotherapy treatment modalities such as Intensity Modulated 
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measurements which enables the inclusion of actual linac output during dose verification 
[4–7]. 
A drawback of 2D detector array measurements is the spatial resolution which is limited 
by the size of a single elementary detector and the center-to-center distance between 
detectors. In particular detector arrays composed of ionization chambers have a limited 
resolution due to the relatively large detector spacing. Poppe et.al. showed that according 
to the Nyquist sampling theorem, IMRT dose reconstruction requires a detector with a 
spatial frequency of 0.4 mm-1 which is higher than commonly available [8]. Prior knowledge 
can help to overcome this limitation, e.g. by use of a lower resolution measurement as a 
correction to a high resolution calculation. An example is the COMPASS system (IBA 
Dosimetry) which reconstructs 3D dose in a patient CT based on 2D measurements obtained 
with a low resolution ionization chamber array (MatriXX, IBA Dosimetry). Differences 
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In a previous study, we showed the limitations of the MatriXX detector in combination 
with the COMPASS system to accurately reconstruct delivered dose in case of MLC leaf 
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Material and method 
Iterative reconstruction method 
The iterative reconstruction method used for MLC leaf position reconstruction was 
implemented using Matlab (version R2014a). It consists of a fluence model, a detector 
model and an optimizer that minimizes differences between measured and modeled 
detector response by adjusting fluence model optimization parameters independent of the 
treatment planning system (figure 1). In terms of dose verification, MLC leaf positions were 
reconstructed and adjusted in the original RT-plan. The adjusted RT-plan and measured 
detector response was then used in combination with the COMPASS system (v2.0) and the 
planning CT for 3D dose reconstruction. 
 
 
Figure 1:  
Reconstruction of MLC positions by an iterative reconstruction method and 2D detector 
measurements. The initial fluence (Ψmodel) is based on the original treatment plan (RT-plan) from the 
treatment planning system (TPS). Subsequently, from the fluence model and the detector model, the 
detector response (Rmodel) is determined. Differences in calculated detector response and measured 
detector response (Rmeas) were minimized by adjusting fluence model optimization parameters. For 
MLC position reconstruction, only a selection of source parameters and MLC leaf positions were 
optimized. Reconstructed MLC leaf positions were implemented in the original treatment plan (RT-
plan*) for a better representation of the actual given treatment plan which was eventually used in 
combination with the measured detector response for 3D dose reconstruction. 
 
Fluence model  
The fluence generated by the linac head was modeled with an RT-plan and the fluence 
model with fluence model parameters that comprised of source parameters, jaw settings 



















Table 1:  
Fluence model optimization parameters. Each parameter could be optimized independently per IMRT 
segment (single optimization) or per IMRT treatment beam (group optimization). For MLC leaf position 
reconstruction, a selection of source parameters and MLC leaf positions were optimized. 
Fluence model optimization parameters Description 
Source 
parameters 
Penumbra Penumbra shape for the primary and secondary 
fluence source in x and y direction. The slope was 
modeled using the error function and could be 
optimized in the +/-x and +/-y direction 
independently allowing asymmetrical beam 
modeling. 
Flattening filter Non-flatness of the beam. The effect of the 
flattening filter is described by a rotational 
symmetry. 
Output Output corrections for the primary and secondary 
fluence source.  
Weight Relative weight  of the primary fluence source 
relative to the secondary fluence source.  
Position Primary and secondary fluence source position in x, 
y, and z direction simulating detector array shifts. 
Angle  Angle correction for the calculated fluence 
simulating detector array in-plane rotation. 
Jaw settings Position Position offset of the x-jaw and y-jaw. 




Leaf tip transmission Systematic offset of all MLC leafs in the x-direction. 
Tongue and groove Overlap of adjacent MLC leafs in the y-direction. 
Leaf position error Shift MLC leaf in x-direction with respect to original 
RT-plan settings. The shift was optimized 
independently for all MLC leafs. 
 
Detector model 
The detector model describes the geometry of the MatriXX detector (IBA, Dosimetry) 
consisting of 1,020 ionization chambers (4.5 (Ø) mm x 5.0 (h) mm, 80.0 mm3). The detector 
response function of an individual ionization chamber of the MatriXX detector was 
simulated by Monte-Carlo simulations using ESGnrc code. A 6MV pencil beam of 1.0 mm 
wide was used for this simulation with an energy cutoff of 0.521 MeV and 0.010 MeV for 





Left: Monte Carlo setup 
of a 6MV pencil beam 
(arrow) simulation for an 
air filled ionization 
chamber (4.5 (Ø) mm x 
5.0 (h) mm, 80.0 mm3) 
with 20.0 mm build-up 
composed of water. 
Right: Monte Carlo 
based detector response 
function for a pencil beam displacement in the lateral direction normalized to the central axis of an 
individual ionization chamber. A clear peak in detector response is seen for a pencil beam position at 




Fluence model parameters were adjusted using the optimizer function fminsearch of 
Matlab. The optimizer minimized the difference between simulated detector response 
(Rmodel) and measured detector response (Rmeas), formula 1.  
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2
  𝑛𝑛𝑖𝑖=1    (1) 
 
with n the number of ionization chambers of the entire detector, ψmodel the energy fluence 
determined according to the fluence model, and x the fluence model optimization 
parameters. Optimization could be performed for each segment independently (e.g. output 
corrections) or per treatment beam (e.g. leaf position reconstruction). 
 
Commissioning 
Commissioning of the fluence model was performed using several treatment fields. A 
20x26 cm2 rectangular field was used to model the source parameters, jaw settings and leaf 
tip transmission. Furthermore, two complementary fields with several inserted MLC leafs 
were used for further modeling the source parameters and the tongue and groove effect of 
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2D detector measurements 
Measurements were performed using the MatriXX Evolution detector (IBA dosimetry). 
The detection time per frame was 300 msec. The detector was fixed to the gantry head 
using a holder from IBA dosimetry. The measurements were performed using an Elekta SLi 
linac with an MLC leaf width projected at the isocenter of 10.0 mm and a nominal beam 
energy of 6MV. The detector consists of 1020 ionization chambers with a spacing of 7.62 
mm and the source to detector distance was 762 mm, such that each leaf pair of the MLC 
was aligned with one row of ionization chambers on the detector. Details of the detector 
were previously published [13]. 
 
Film measurements 
Film measurements were used to demonstrate the impact of reconstructed MLC leaf 
positions on the dose deposition for one clinical head and neck IMRT treatment field. 
Radiochromic films (Gafchromic EBT2, ISP Corp.) were positioned in coronal orientation in 
the middle of a 30x30x10 cm3 solid water phantom. The day after irradiation the films were 
scanned on a commercial flatbed scanner (V700, Epson), followed by conversion of optical 
density to dose. The conversion method was corrected for non-uniformity artifacts intrinsic 
in flatbed film scanners [14,15]. Film inhomogeneities were corrected using a double 
exposure procedure [16]. 
 
MLC leaf position reconstruction 
MLC leaf position error detection performance of the iterative reconstruction method 
was evaluated for various error locations relative to the ionization chamber, a range of 
introduced error sizes, varying noise levels (i.e. monitor unit  (MU) dependency), and for 
ten clinical IMRT treatment beams (each beam was obtained from a treatment plan of a 
different patient). First, the output was optimized per segment (single optimization). 
Second, the source position was optimized per treatment field (group optimization), and 
finally, individual MLC leaf positions were reconstructed per treatment field (group 
optimization). Furthermore, one clinical head and neck IMRT treatment beam was used to 
demonstrate the difference between the iterative reconstruction method and the 
correction kernel method [10] in comparison to film measurements. Iterative MLC leaf 
reconstruction was performed on a basic desktop PC (Intel Core 3.2 GHz), and all RT-plans 




Error location dependency 
To test whether the accuracy of reconstructed leaf positions depended on the location 
of the MLC leaf tip relative to the ionization chambers, a rectangular field (10x26 cm2) 
covering half of the detector up to the middle with an MLC leaf position error of 5.0 mm 
was used (same treatment field as included in figure 4a in the results section). The 26 MLC 
leafs with off-axis leaf tip positions were moved 15.0 mm in steps of one millimeter, thus 
two ionization chambers were passed by each leaf. 
 
Error size dependency 
Error size dependency was tested using two treatment fields. The first field was 
identical to the treatment field used to evaluate the error location dependency; a 
rectangular field covering half of the detector up to the middle. MLC leaf position errors 
ranged from -1.0 mm to 5.0 mm. The second field was an irregular field (approximately 
20x26cm2) with introduced MLC leaf positon errors by inserting or retracting MLC leafs from 
-10.0 mm to 10.0 mm (same treatment field as included in figure 4b in the results section). 
Leaf displacements occurred every three leafs. Two subsequent leafs were kept at their 
nominal positions and every third leaf was displaced. This field was also used to test 
whether MLC leafs at their nominal position next to an MLC leaf with an introduced 
positional error were affected by the iterative reconstruction method. 
 
Gantry angle dependency 
Korevaar et. al. showed that dose verification performed with the MatriXX detector was 
affected by gravity due to changing gantry angles used for IMRT [9]. Whether gravity had 
an effect on MLC leaf position reconstruction was tested with the same irregular field used 
for error size dependency for a gantry angle of 0o and 90o. 
 
Monitor unit dependency 
Influence of the noise level for 2D measurements on the accuracy of MLC leaf position 
reconstruction was tested by varying MU’s for irradiation. MU ranged from 2.5 MU (1 
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Clinical IMRT treatment beams 
Error detection performance of the iterative reconstruction method for clinical IMRT 
treatment beams was tested for ten patients (two prostate, and eight head and neck 
treatment plans). For each patient, one treatment beam was evaluated with an MLC leaf 
position error of 2.0 mm, 4.0 mm and 6.0 mm for randomly selected leafs. The treatment 
beams consisted of various segments ranging between 4 to 15 segments.  
To demonstrate the effect of the iterative reconstruction method on the dose 
deposition in comparison to dose reconstruction artifacts caused by the correction kernel 
method, one treatment beam of a clinical head and neck IMRT treatment plan was used. 
The treatment beam was composed of 12 segments with introduced errors of 5.0 mm for 
five MLC leafs. The treatment beam was measured first with a high resolution film inside a 
solid-water phantom, and second using the MatriXX detector. Dose reconstruction based 
on MatriXX measurements was done using the COMPASS system (v2.0) on a 2x2x2 mm3 
dose grid, with and without the iterative reconstruction method. When no iterative 
reconstruction was performed, differences in measured and calculated detector response 
were corrected only by the correction kernel. Measurements were performed at a gantry 




Error location dependency 
Error detection results for the rectangular field with an introduced error of 5.0 mm 
indicated that the reconstruction of the MLC leaf position was independent of the leaf 
position with respect to the ionization chamber positions. The introduced error was 
reconstructed with an accuracy of +/- 0.5 mm for 15 consecutive MLC leaf positions on the 
detector (figure 3).  
 
Error size dependency 
The iterative reconstruction method was capable of detecting MLC leaf position 
errors with millimeter accuracy (figure 4). For the rectangular field, error sizes ranging from 
-1.0 mm to 5.0 mm were correctly reconstructed for all leafs (n=26) with an accuracy within 
1.0 mm. For the irregular field, reconstruction of individual MLC leaf positional errors 
ranging from -10.0 mm to 10.0 mm was performed with sub-millimeter accuracy for 98% of 
the leafs. Only one MLC leaf with an introduced error of -10.0 mm resulted in a residual 
error of -1.1 mm. The remaining errors were all reconstructed within -1.0 mm or 1.0 mm 
accuracy. For the irregular field, the iterative reconstruction method led to minor positional 
errors for individual MLC leafs which were positioned on their nominal position (i.e. an 




Reconstruction of MLC leaf positions with 5.0 
mm errors for the rectangular field at 15 
consecutive MLC leaf positions. In red: actual 
leaf position. Each data point corresponds to 
the pooled mean reconstructed leaf position 
for all individual leafs (26 in total for each 
position). The error bars indicate one standard 
deviation of the pooled reconstructed leaf 
positions. Each MLC leaf passed at least two 
ionization chambers. The accuracy of 
reconstructed leaf positions was not affected 
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Figure 4:  
Illustration of the rectangular (a) and irregular (b) treatment fields showing MLC and ionization 
chambers positions. The boxplots show the residual error of reconstructed MLC leaf positions 
compared to the actual leaf positions for the rectangular field (c with n=26 for each introduced error) 
and irregular field (d with n=36 for an introduced error of 0 mm, and n=1 for each other introduced 
error). 
 
Gantry angle dependency 
The iterative reconstruction method showed to be sensitive for the gantry angle used 
for irradiation. Due to the weight of the MatriXX detector and its holder, the system was 
affected by gravity resulting in reconstructed MLC leaf positons with a systematic offset of 








Monitor unit dependency 
The number of MU’s had little effect on the accuracy of reconstruction of MLC leaf 
positions as the majority of MLC leaf positions changed less than 0.1 mm for measurements 
in the range of 2.5 MU to 200 MU (figure 5). Furthermore, variation of MLC leaf position 
change reduced with increasing monitor units. 
 
Clinical IMRT treatment beams 
Introduced MLC leaf position errors of 2.0 mm, 4.0 mm and 6.0 mm for ten clinical 
IMRT treatment beams were reconstructed with millimeter accuracy (figure 6). The iterative 
reconstruction method resulted in a mean residual error of -0.04±0.53 mm, 0.01±0.62 mm, 
0.27±0.47 mm, and 0.40±0.61 mm for MLC positional errors of 0.0 mm, 2.0 mm, 4.0 mm, 
and 6.0 mm respectively. For MLC leafs positioned at their nominal position, a residual error 
exceeding -1.0 mm or 1.0 mm was observed for 4.1% (n=15) of all MLC leafs (n=362). 
Furthermore, an underestimation of the introduced MLC leaf position error for three MLC 
leafs with an introduced error of 4.0 mm (one out of ten) and 6.0 mm (two out of ten) 
resulted in an residual error larger than 1.0 mm.  
Figure 5:  
Boxplot of the MLC leaf position change 
for varying monitor units ranging from 
2.5 MU to 200 MU for the irregular 
treatment field. One detection frame of 
300 msec corresponded to 2.5 MU. The 
MLC leaf position change was the 
difference with the residual error at 200 
MU (80 frames) for all leafs (n=52). 
Outliers for 2.5, 5.0, 10.0, and 50.0 MU 
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For a clinical head and neck 
IMRT treatment beam, the 
iterative reconstruction method 
reduced dose reconstruction 
artifacts (blurring caused by the 
correction kernel method) of the 
COMPASS system (figure 7). Note, 
MLC leaf position errors occurred 
in all 12 segments resulting in dose 
reconstruction errors at various 
positions. The correction kernel 
was applied to differences 
between measured and expected 
response caused by incorrect MLC 
leaf positioning. The iterative 
reconstruction method was able to 
correctly detect the 5.0 mm error 
with a millimeter accuracy resulting in a residual error of 0.22±0.35 mm. Using the corrected 
RT-plan with reconstructed MLC leaf positions, the dose reconstructed by the COMPASS 
system showed less blurring of the dose (figure 7d) than the correction kernel method 
(figure 7c), and was in better agreement with the film measurement (figure 7e). MLC leaf 
position reconstruction was performed within 17 minutes.  
Figure 6:  
Residual error of reconstructed MLC leaf positions for 
introduced errors of 0.0 mm (n=362), 2.0 mm (n=10), 
4.0 mm (n=10), and 6.0 mm (n=10) for ten clinical 





Effect of 5.0 mm introduced position errors for five MLC leafs in all 12 IMRT segments of a clinical head 
and neck treatment beam. The top two images illustrate the difference between the expected and 
detected detector response for the COMPASS system without (a) and with (b) the iterative 
reconstruction method. The arrows indicate the MLC leafs for which errors were introduced. The 
middle and bottom images illustrate the dose differences (%, relative to the prescribed dose for 
reconstructed dose with MLC leaf position errors minus reconstructed dose without MLC leaf position 
errors) as detected by the COMPASS system in combination with the correction kernel method (c), the 
COMPASS system in combination with the iterative reconstruction method (d), and film dosimetry (e; 
film dose with MLC leaf position errors minus film dose without MLC leaf position errors). The 
difference between the dose reconstructed by the COMPASS system with (c) and without (d) the 
iterative reconstruction method is given in (f). The 20 cGy isodose line is represented. The colorbar 
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in all 12 segments resulting in dose 
reconstruction errors at various 
positions. The correction kernel 
was applied to differences 
between measured and expected 
response caused by incorrect MLC 
leaf positioning. The iterative 
reconstruction method was able to 
correctly detect the 5.0 mm error 
with a millimeter accuracy resulting in a residual error of 0.22±0.35 mm. Using the corrected 
RT-plan with reconstructed MLC leaf positions, the dose reconstructed by the COMPASS 
system showed less blurring of the dose (figure 7d) than the correction kernel method 
(figure 7c), and was in better agreement with the film measurement (figure 7e). MLC leaf 
position reconstruction was performed within 17 minutes.  
Figure 6:  
Residual error of reconstructed MLC leaf positions for 
introduced errors of 0.0 mm (n=362), 2.0 mm (n=10), 
4.0 mm (n=10), and 6.0 mm (n=10) for ten clinical 





Effect of 5.0 mm introduced position errors for five MLC leafs in all 12 IMRT segments of a clinical head 
and neck treatment beam. The top two images illustrate the difference between the expected and 
detected detector response for the COMPASS system without (a) and with (b) the iterative 
reconstruction method. The arrows indicate the MLC leafs for which errors were introduced. The 
middle and bottom images illustrate the dose differences (%, relative to the prescribed dose for 
reconstructed dose with MLC leaf position errors minus reconstructed dose without MLC leaf position 
errors) as detected by the COMPASS system in combination with the correction kernel method (c), the 
COMPASS system in combination with the iterative reconstruction method (d), and film dosimetry (e; 
film dose with MLC leaf position errors minus film dose without MLC leaf position errors). The 
difference between the dose reconstructed by the COMPASS system with (c) and without (d) the 
iterative reconstruction method is given in (f). The 20 cGy isodose line is represented. The colorbar 

















MLC leaf positions can be reconstructed successfully using an iterative reconstruction 
method in combination with low resolution 2D ionization chamber array measurements. 
Even with a spatial resolution of 1.0 cm (isocenter distance projected spacing between two 
ionization chambers of the MatriXX detector with a source to detector distance of 76.2 cm), 
MLC leaf positions were reconstructed with millimeter accuracy independent of the 
position of the MLC relative to the ionization chambers and for low MU’s. This is in line with 
MLC leaf position reconstruction research discussed in literature [17,18]. Furthermore, 
results of this study showed that the iterative reconstruction method also introduces minor 
positional errors for MLC leafs with no introduced errors. The majority of these minor 
positional errors were all within -1.0 mm or 1.0 mm which complies with MLC leaf position 
tolerance levels discussed in the AAPM TG-142 report [19]. For the clinical IMRT treatment 
beam with introduced MLC leaf positional errors of 4.0 mm and 6.0 mm three out of twenty 
MLC leafs exceeded MLC leaf positional tolerance levels. For MLC leafs with positional 
errors after reconstruction, differences between calculated and measured detector 
response is detected by the COMPASS system and corrected for using the correction kernel 
method. Reconstructed leaf positions were in better agreement with leaf positions of the 
measurement for the iterative reconstruction method as compared to the correction kernel 
method, thus reducing dose reconstruction artifacts introduced by the correction kernel. 
When introducing such an MLC leaf position reconstruction system in clinical QA, MLC leaf 
position reconstruction accuracy should at least comply with the AAPM-TG 142 report [19]. 
The iterative reconstruction method would benefit from a faster calculation procedure as 
the reported reconstruction time of one clinical treatment beam composed of 12 segments 
takes about 17 minutes which is a drawback for routine clinical QA. 
The described iterative reconstruction method allows robust MLC leaf position 
detection. Inclusion of actual linac output also enables the detection of a rotational and/or 
positional shift of the detector in the treatment field. Nevertheless, the fluence model is 
relatively simple and limited as multiple optimization parameters affect several beam 
properties. A skewed beam for instance can cause incorrect modeling of the penumbra 
slope. This underlines the need for accurate commissioning as described in literature [20]. 
For this study, the two treatment fields used for commissioning fluence parameters and 
MLC properties were found to be sufficient. Even so, one has to be aware that errors can 
occur even when commissioning has been performed accurately. This can be overcome by 
including a pre-irradiation to verify the beam model with the detector response prior to 
actual MLC leaf position reconstruction. Errors in the detector model can cause errors in 
 
 
reconstructed MLC leaf positions as well. We found that after optimization, differences 
between measured and modeled detector response remained resulting in minor positional 
errors for MLC leafs with no introduced error. This could be caused by inaccuracies in the 
fluence and detector response models but also be attributed to limitations in the 
optimization related to incomplete convergence or the existence of local minima. Even so, 
the simplicity of the applied fluence and detector models illustrate the power of the 
iterative reconstruction method which lead to millimeter accuracy of MLC leaf position 
reconstruction enabling high accuracy 3D dose verification. 
In theory, the described iterative reconstruction method can be used in combination 
with several detector types as the detector response function is exchangeable. An array of 
detector elements present nonetheless advantages in terms of dosimetry as the detector 
response functions of adjacent detector elements are overlapping which enables a 
measurement of the field edge displacement even between two detector elements. In this 
study, the measurement setup allowed only one pair of MLC leafs to block one row of 
ionization chambers. Therefore, the detector response function of a single ionization 
chamber was mainly affected by one MLC leaf. There are however situations, for instance 
using high resolution MLC systems, in which one leaf pair is not aligned with one row of 
ionization chambers. This can result in various MLC settings with a similar detector 
response. Further analyses are necessary to test the system for high resolution MLC 
systems.  
Due to the weight of the detector and the holder, gravity effects appear and MLC leaf 
position reconstruction is affected by the gantry angle. This could be incorporated as a 
minor shift.  Furthermore, because the detector has to be mounted on the linac and can 
only be used for pretreatment dose verification, no information can be obtained during the 
actual treatment. This could be solved by the use of a transmission detector [21,22], 
including MLC log file information [23,24] or by a different method of MLC position 
reconstruction [25].  
For this study, the iterative reconstruction method was evaluated for IMRT which is 
based on a step and shoot approach. In theory, the described methodology is also applicable 
for VMAT or other techniques which introduce dynamic leaf displacement during 
treatment. This would require a modification of the fluence model to integrate fluence 
within a time interval; e.g. the time per control point. Different approaches of dynamic leaf 
displacement on dose reconstruction using EPID systems or Monte Carlo simulations have 






MLC leaf positions can be reconstructed successfully using an iterative reconstruction 
method in combination with low resolution 2D ionization chamber array measurements. 
Even with a spatial resolution of 1.0 cm (isocenter distance projected spacing between two 
ionization chambers of the MatriXX detector with a source to detector distance of 76.2 cm), 
MLC leaf positions were reconstructed with millimeter accuracy independent of the 
position of the MLC relative to the ionization chambers and for low MU’s. This is in line with 
MLC leaf position reconstruction research discussed in literature [17,18]. Furthermore, 
results of this study showed that the iterative reconstruction method also introduces minor 
positional errors for MLC leafs with no introduced errors. The majority of these minor 
positional errors were all within -1.0 mm or 1.0 mm which complies with MLC leaf position 
tolerance levels discussed in the AAPM TG-142 report [19]. For the clinical IMRT treatment 
beam with introduced MLC leaf positional errors of 4.0 mm and 6.0 mm three out of twenty 
MLC leafs exceeded MLC leaf positional tolerance levels. For MLC leafs with positional 
errors after reconstruction, differences between calculated and measured detector 
response is detected by the COMPASS system and corrected for using the correction kernel 
method. Reconstructed leaf positions were in better agreement with leaf positions of the 
measurement for the iterative reconstruction method as compared to the correction kernel 
method, thus reducing dose reconstruction artifacts introduced by the correction kernel. 
When introducing such an MLC leaf position reconstruction system in clinical QA, MLC leaf 
position reconstruction accuracy should at least comply with the AAPM-TG 142 report [19]. 
The iterative reconstruction method would benefit from a faster calculation procedure as 
the reported reconstruction time of one clinical treatment beam composed of 12 segments 
takes about 17 minutes which is a drawback for routine clinical QA. 
The described iterative reconstruction method allows robust MLC leaf position 
detection. Inclusion of actual linac output also enables the detection of a rotational and/or 
positional shift of the detector in the treatment field. Nevertheless, the fluence model is 
relatively simple and limited as multiple optimization parameters affect several beam 
properties. A skewed beam for instance can cause incorrect modeling of the penumbra 
slope. This underlines the need for accurate commissioning as described in literature [20]. 
For this study, the two treatment fields used for commissioning fluence parameters and 
MLC properties were found to be sufficient. Even so, one has to be aware that errors can 
occur even when commissioning has been performed accurately. This can be overcome by 
including a pre-irradiation to verify the beam model with the detector response prior to 
actual MLC leaf position reconstruction. Errors in the detector model can cause errors in 
 
 
reconstructed MLC leaf positions as well. We found that after optimization, differences 
between measured and modeled detector response remained resulting in minor positional 
errors for MLC leafs with no introduced error. This could be caused by inaccuracies in the 
fluence and detector response models but also be attributed to limitations in the 
optimization related to incomplete convergence or the existence of local minima. Even so, 
the simplicity of the applied fluence and detector models illustrate the power of the 
iterative reconstruction method which lead to millimeter accuracy of MLC leaf position 
reconstruction enabling high accuracy 3D dose verification. 
In theory, the described iterative reconstruction method can be used in combination 
with several detector types as the detector response function is exchangeable. An array of 
detector elements present nonetheless advantages in terms of dosimetry as the detector 
response functions of adjacent detector elements are overlapping which enables a 
measurement of the field edge displacement even between two detector elements. In this 
study, the measurement setup allowed only one pair of MLC leafs to block one row of 
ionization chambers. Therefore, the detector response function of a single ionization 
chamber was mainly affected by one MLC leaf. There are however situations, for instance 
using high resolution MLC systems, in which one leaf pair is not aligned with one row of 
ionization chambers. This can result in various MLC settings with a similar detector 
response. Further analyses are necessary to test the system for high resolution MLC 
systems.  
Due to the weight of the detector and the holder, gravity effects appear and MLC leaf 
position reconstruction is affected by the gantry angle. This could be incorporated as a 
minor shift.  Furthermore, because the detector has to be mounted on the linac and can 
only be used for pretreatment dose verification, no information can be obtained during the 
actual treatment. This could be solved by the use of a transmission detector [21,22], 
including MLC log file information [23,24] or by a different method of MLC position 
reconstruction [25].  
For this study, the iterative reconstruction method was evaluated for IMRT which is 
based on a step and shoot approach. In theory, the described methodology is also applicable 
for VMAT or other techniques which introduce dynamic leaf displacement during 
treatment. This would require a modification of the fluence model to integrate fluence 
within a time interval; e.g. the time per control point. Different approaches of dynamic leaf 
displacement on dose reconstruction using EPID systems or Monte Carlo simulations have 






The introduced iterative reconstruction method is shown to allow reconstructing of 
individual MLC leaf positions with a millimeter accuracy using a low resolution ionization 
chamber detector array. By implementing reconstructed MLC leaf positions in the original 
RT-plan, the adjusted RT-plan gives a better representation of the actual given treatment 
enabling high accuracy 3D dose verification. The algorithm is independent of the position of 
the ionization chamber in the field, variations in MU’s, and can reduce artifacts in dose 
reconstruction caused by incorrect MLC leaf positions such as reported previously in 3D 
dose reconstruction implementations. The introduced iterative reconstruction method is a 
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FOR INTENSITY MODULATEDRADIOTHERAPY 
(IMRT)
Chapter 4
Reconstruction of high resolution MLC leaf 
positions using a low resolution detector for 











In pre-treatment dose verification, low resolution detector systems are unable to identify 
shifts of individual leafs of high resolution multi leaf collimator (MLC) systems from 
detected changes in the dose deposition. The goal of this study was to introduce an 
alternative approach (the shutter technique) combined with a previous described iterative 
reconstruction method to accurately reconstruct high resolution MLC leaf positions based 
on low resolution measurements. For the shutter technique, two additional radiotherapy 
treatment plans (RT-plans) were generated in addition to the original RT-plan; one with 
even MLC leafs closed for reconstructing uneven leaf positions and one with uneven MLC 
leafs closed for reconstructing even leaf positions. Reconstructed leaf positions were then 
implemented in the original RT-plan for 3D dose reconstruction. The shutter technique 
was evaluated for a 6 MV Elekta SLi linac with 5 mm MLC leafs (AgilityTM) in combination 
with the MatriXX Evolution detector with detector spacing of 7.62 mm. Dose 
reconstruction was performed with the COMPASS system (v2.0). The measurement setup 
allowed one row of ionization chambers to be affected by two adjacent leaf pairs. 
Measurements were obtained for various field sizes with MLC leaf position errors ranging 
from 1.0 mm to 10.0 mm. Furthermore, one clinical head and neck IMRT treatment beam 
with MLC introduced leaf position errors of 5.0 mm was evaluated to illustrate the impact 
of the shutter technique on 3D dose reconstruction. Without the shutter technique, MLC 
leaf position reconstruction showed reconstruction errors up to 6.0 mm. Introduction of 
the shutter technique allowed MLC leaf position reconstruction for the majority of leafs 
with sub-millimeter accuracy resulting in a reduction of dose reconstruction errors. The 
shutter technique in combination with the iterative reconstruction method allows high 
resolution MLC leaf position reconstruction using low resolution measurements with sub-
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Several techniques and systems have been described for pre-treatment dose 
verification of advanced radiotherapy treatment techniques such as intensity modulated 
radiotherapy (IMRT) [1–4]. The COMPASS system (IBA Dosimetry) is a pre-treatment dose 
verification system which can reconstruct a 3D dose deposition in patient CT data using 2D 
measurements obtained by an array of ionisation chambers (MatriXX, IBA Dosimetry). 
However, when measured using this method, limited spatial resolution is obtained. In 
relation to current high resolution multi leaf collimators (MLC) these low resolution 
detector arrays do not meet the Nyquist sampling theorem which could result in incorrect 
dose reconstruction [5]. This limitation is compensated for by the COMPASS system by 
using a correction kernel method, which corrects the calculated detector response used 
for dose calculations according to the measured detector response [6]. Even though the 
correction kernel reduces dose reconstruction artefacts allowing adequate pre-treatment 
dose verification, local dose inaccuracies still occur [7]. 
In a previous study we introduced an iterative reconstruction method to compensate 
for the limitation of low resolution detector arrays for high resolution dose reconstruction 
[8]. Based on 2D measurements and a simplified fluence model, detector model and 
optimizer, actual MLC leaf positions were reconstructed with millimetre accuracy and 
were well within tolerance levels (95% of the error counts <3.5 mm for step and shoot 
IMRT) as described in the AAPM-TG 142 report [9]. Reconstructed MLC leaf positions were 
adjusted in the original RT-plan for a better representation of the actual given treatment 
plan. The iterative reconstruction method was tested for an MLC consisting of one 
centimetre leafs. The measurement setup allowed one row of ionisation chambers to be 
affected by one leaf pair during measurements. Technological developments have led to 
new improved MLC’s with leafs of less than one centimetre. For the MatriXX detector, one 
row of ionisation chambers can then be affected by multiple leaf pairs which could lead to 
a similar detector response for different MLC leaf positions. This effect has not been 
accounted for by the iterative reconstruction method and can result in incorrect 
reconstruction of actual MLC leaf positions. Therefore, the main objective of this study 
was to demonstrate the impact of incorrect MLC leaf position reconstruction on 3D dose 
reconstruction using the COMPASS system and to introduce an alternative approach to 
accurately reconstruct leaf positions of a high resolution MLC based on low resolution 
detector measurements.  
  
Materials and Methods  
Radiotherapy treatment plans (RT-plan) were generated in Pinnacle (v9.0) and 2D 
measurements were obtained with an ionization chamber array (MatriXX Evolution, IBA 
Dosimetry). The detector was mounted on a 6MV Elekta SLi linac with a high resolution 
MLC consisting of 5.0 mm leafs (AgilityTM). One row of ionization chambers could be 
affected by two adjacent leaf pairs due to a detector spacing of 7.62 mm and a source to 
detector distance of 762 mm.  
To reduce 3D dose reconstruction errors caused by the combination of incorrect MLC 
leaf positioning, high resolution of the MLC, and the characteristics of the correction 
kernel method implemented in the COMPASS system [7], an alternative approach was 
introduced. The original treatment plan was adjusted in such a way that the detector 
response of a single ionization chamber row was affected by one MLC leaf pair instead of 
two. This was realized by closing even or uneven leafs during MLC leaf position 
reconstruction, assuming that individual MLC leaf positions errors were systematic and 
unaffected by neighbouring leafs during the process. Therefore, for each original RT-plan, 
two new RT-plans were created using Matlab (version R2014a); one with even leafs closed 
and one with uneven leafs closed; i.e. the shutter technique. Uneven MLC leaf positions 
were reconstructed using the RT-plan with even leafs closed and even MLC leaf positions 
were reconstructed using the RT-plan with uneven leafs closed. Finally, reconstructed MLC 
leaf positions were implemented in the original RT-plan which was used for 3D dose 
verification using the COMPASS system (v2.0). When no shutter technique was applied, 
differences between expected and measured detector response were corrected using the 
correction kernel method implemented in the COMPASS system [6]. 
 
Iterative reconstruction method 
MLC leaf positions were reconstructed using an in house developed (Matlab R2014a) 
iterative reconstruction method as described in our previous study [8]. It consists of a 
simplified fluence model, a detector model and an optimizer (figure 1). Based on a 
radiotherapy treatment plan (RT-plan) a fluence is calculated. The calculated fluence is 
then used in combination with the detector model to predict the expected detector 
response. Subsequently, the optimizer minimized the differences between the expected 
and measured detector response by adjusting MLC leaf positions.  
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Flow chart of 3D dose verification using high resolution MLC’s and low resolution 2D detector 
measurements in combination with the iterative reconstruction method. Based on the original 
treatment plan (RT-planorig), two new treatment plans were generated using Matlab with even and 
uneven MLC leafs closed (RT-planShutter (2x)); i.e. the shutter technique. Based on the expected fluence 
of the two newly created RT-plans (ψModelSutter (2x)), expected detector responses were calculated 
(RmodelShutter (2x)). Differences between expected and measured detector responses (RMeasShutter (2x)) 
were then minimized by optimizing MLC leaf positions. Reconstructed MLC leaf positions were finally 
implemented in the original treatment plan (RT-plan*) and used for 3D dose verification in 
combination with the measurement of the original treatment field (RmeasOrig). 
  
3D dose reconstruction error 
For a 3D dose reconstruction performed with the COMPASS system, the correction 
kernel method only corrects for differences between expected and measured detector 
response. And because a low resolution detector can give a single detector response for 
various MLC leaf positions, completely different 3D dose reconstructions can be calculated 
for a single measurement. To illustrate this limitation, two rectangular fields of 15x20 cm2, 
one with even leafs closed and one with uneven leafs closed were used. For both 
treatment fields, the detector response was obtained using the MatriXX detector and the 
dose was reconstructed in a 30x30x10 cm3 solid water phantom on a 2x2x2 mm3 dose grid 




















Film measurements of a clinical head and neck IMRT treatment field were used to 
demonstrate the impact of MLC leaf position reconstruction on the dose deposition. 
Radiochromic films (Gafchromic EBT2, ISP Corp.) were placed in the middle of a 30x30x10 
cm3 solid water phantom and scanned on a commercial flatbed scanner (V700, Epson) the 
day after irradiation. Conversion of optical density to dose was corrected for non-
uniformity artefacts of the flatbed scanner [10,11], and a double exposure procedure 
technique was performed to correct for film inhomogeneities [12]. 
 
MLC leaf position reconstruction 
Error size dependency 
Error size dependency was tested using one rectangular treatment field of 
approximately 15x20 cm2 with introduced leaf position errors ranging from 1.0 mm to 
10.0 mm in the left and right MLC leaf bank. Leaf displacements were introduced every 
four leafs. One leaf was displaced and three subsequent MLC leafs were kept at their 
nominal position. MLC leaf positions were reconstructed with and without the shutter 
technique. For the shutter technique, two additional RT-plans were created and two 
additional 2D detector array measurements were obtained.  
 
Clinical head and neck IMRT treatment beam 
One IMRT treatment beam of a clinical head and neck cancer patient was used to 
illustrate the effect of MLC leaf position reconstruction on the dose deposition. The dose 
reconstruction performed with the correction kernel method and shutter technique were 
evaluated with film measurements as a reference. The beam consisted of 13 segments 
with an introduced 5.0 mm leaf positioning error for five MLC leafs. MLC leaf positions 
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3D dose reconstruction error 
Measurements obtained for two rectangular fields (15x20 cm2), one with even leafs 
closed, and one with uneven leafs closed resulted in a similar detector response (figure 2). 
Due to a minimal offset of the collimator block with retracted leafs behind it the effective 
leaf opening at the edge of the field was larger resulting in a peak in detector response at 
position -10.0 cm for the measurement with even leafs closed (figure 2, top left). As 
expected, for each treatment field the reconstructed dose showed different dose profiles 
due to different MLC leaf positioning (figure 2, right). However, information on MLC 
positioning could not be derived from the difference in detector response (figure 2, left). 
These results confirmed that a similar detector response could correspond to completely 
different dose depositions emphasizing the need for accurate MLC leaf position 
reconstruction for accurate dose verification.  
 
Figure 2: 
A similar detector response 
(left) with different dose 
reconstruction results 
(right) for a rectangular 
treatment field (15x20 
cm2) with even leafs closed 
(top) and uneven leafs 
closed (bottom). The y-
direction is perpendicular 
to the direction of the movement of MLC leafs. Detector response and reconstructed dose was 
normalized to the maximum value of the treatment field with even leafs closed.  
 
Error size dependency  
The shutter technique resulted in a substantial improvement of MLC leaf position 
error detection (figure 3). For the shutter technique, the majority of MLC leaf positions 
were reconstructed with sub-millimeter accuracy. Without the shutter technique, the 
iterative reconstruction method was unable to discriminate between the contribution of 
two neighbouring MLC leafs to one detector row of ionization chambers resulting in large 























































Residual error of reconstructed MLC 
leaf positions for 40 leaf pairs of the 
left and right leaf bank. MLC leaf 
positions were reconstructed with 
and without the shutter technique 
for leafs placed at their nominal 
position (white) and for leafs with 
introduced errors (grey) ranging 
from 1.0 mm to 10.0 mm. The vertical dashed line shows the boundary of a residual error of 1.0 mm. 
 
Clinical head and neck IMRT treatment beam 
For the shutter technique, introduced MLC leaf position errors of 5.0 mm for five MLC 
leafs were reconstructed with sub-millimeter accuracy. Consequently, the shutter 
technique showed a better dose difference agreement between the expected (figure 4B) 
and reconstructed (figure 4C) dose error for MLC leafs with positional errors in 
comparison to the correction kernel method (figure 4A). For the film measurement (figure 
4B), minor over- and under dosage were seen at the edges of the treatment field 
indicating a film registration inaccuracy in the lateral direction. In total, 2 out of 54 MLC 
leafs positioned at their nominal position resulted in a residual error larger than 1.0 mm 
(1.2 mm and 1.3 mm). Consequently over dosage artefacts were seen in the top middle 




errors due to MLC 
leaf position errors 
determined from film 
measurement (B) and 
reconstructed dose 
error without (A) and with (C) the shutter technique. Blue corresponded to an underdosage, thus an 
MLC leave was shifted in the treatment field, blocking part of the fluence. Red corresponded to an 
overdosage, thus an MLC leave was shifted outside the treatment field. The 20 cGy and 40 cGy is 
represented. The colorbar represents the percentage dose differences relative to the prescribed dose 
caused by MLC leaf position errors. Comparison of difference between (A) and (B) versus difference 
between (C) and (B) shows that the shutter technique better identifies the introduced errors. 
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Residual error of reconstructed MLC 
leaf positions for 40 leaf pairs of the 
left and right leaf bank. MLC leaf 
positions were reconstructed with 
and without the shutter technique 
for leafs placed at their nominal 
position (white) and for leafs with 
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Clinical head and neck IMRT treatment beam 
For the shutter technique, introduced MLC leaf position errors of 5.0 mm for five MLC 
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and reconstructed (figure 4C) dose error for MLC leafs with positional errors in 
comparison to the correction kernel method (figure 4A). For the film measurement (figure 
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Discussion 
Results of this study showed that the iterative reconstruction method combined with 
the principle of the shutter technique allows accurate leaf position reconstruction of high 
resolution MLC using low resolution detector array measurements and the combined 
method was found suitable for 3D dose verification purposes. Dose reconstruction errors 
of the shutter technique showed a better similarity with film measurements in comparison 
to dose reconstruction errors of the correction kernel method used by the COPMASS 
system in case of an MLC leaf position mismatch. Although the film measurements 
showed to have a mis-registration in the lateral direction, no increase in blurring of the 
reconstructed dose error is expected and therefore the similarity between error 
reconstruction with the shutter technique is expected superior to error reconstruction 
without the shutter technique. By implementing reconstructed MLC leaf positions in the 
RT-plan, a better representation of actual leaf positions was used for dose verification and 
dose reconstruction errors otherwise introduced by the correction kernel method were 
therefore reduced.  
For the measurement setup of this study two adjacent leafs affected one row of 
ionization chambers. By reconstructing even and uneven MLC leaf positions 
independently, the contribution of even and uneven leafs to the treatment field could be 
determined correctly allowing accurate leaf position reconstruction. Whenever three or 
more MLC leafs affect one row of ionization chambers, the current approach will most 
likely be inadequate. As an alternative to the shutter technique, Poppe et. al. introduced 
an alternative method by shifting the detector parallel and/or perpendicular to the MLC 
leafs which also shows potential for high resolution dose reconstruction using low 
resolution detector arrays [5]. Even though this technique showed to be appropriate for 
dose verification purposes of IMRT, no conclusive information on individual high 
resolution MLC leaf positions can be derived due to the relatively low resolution of the 
measurement in relation to the leafs. This could be improved by adjusting the detector 
model of the iterative reconstruction method as it is applicable for various linear 
accelerators and detector systems when modelled correctly. 
Error detection performance can be affected by inaccuracies in the detector model, 
fluence model, optimizer and/or the MLC system itself. The contribution of each source to 
incorrect leaf position reconstruction is difficult to determine. Nevertheless, the iterative 
reconstruction method has already been tested thoroughly and showed to be capable of 
accurately reconstructing MLC leaf positions errors independent of the position of the leaf 
position error in the treatment field, the size of the leaf position error, the gantry angle 
and the number of monitor units [8]. For the high resolution MLC system used in this 
study modelling of the fluence model showed to be difficult. This is currently performed 
with the same detector as used for MLC leaf position reconstruction. In particular the 
tongue and groove effect was difficult to model due to the low detector resolution. Even 
so, the majority of all MLC leafs were reconstructed with sub-millimeter accuracy and 
were well within MLC leaf position tolerance levels for step and shoot IMRT (95% of the 
error counts <3.5 mm) as discussed in the AAPM TG-142 report [9]. 
An important limitation of the shutter technique is the reduction of time efficiency as 
it is a labour intensive procedure. And even though several aspects of the shutter 
technique such as obtaining two extra RT-plans can be automated, the described 
approach still demands two additional measurements which decreases efficiency 
substantially. Furthermore, as the number of complex radiotherapy treatments which 
need pre-treatment dose verification increases, departmental resources need to be used 
efficiently. Nevertheless, research has shown that a department with a high quality 
treatment machine, competent staff and an accurately modelled treatment planning 
system can achieve a pass rate of 99.5% for treatment plans with no relevant dose 
differences [13]. This underlines the possibility of performing pre-treatment dose 
verification by dose calculations without the need for a measurement-based dose 
reconstruction for each individual RT-plan consequently improving the efficiency of the 
quality assurance procedure [14]. 
  
Conclusion 
The iterative reconstruction method combined with the described shutter technique 
allows high resolution MLC leaf position reconstruction using low resolution 
measurements. By reconstructing even and uneven MLC leaf positions independently, low 
resolution ionization chamber array measurements can be used for pre-treatment high 
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FOR INTENSITY MODULATEDRADIOTHERAPY 
(IMRT)
Chapter 5
Efficient and reliable 3D dose quality assurance 


















Purpose: Advanced radiotherapy treatments require appropriate Quality Assurance (QA) to 
verify 3D dose distributions. Moreover, increase in patient numbers demand efficient QA-
methods. In this study, a time efficient method that combines model-based QA and 
measurement-based QA was developed; i.e. the hybrid-QA. The purpose of this study was 
to determine the reliability of the model-based QA and to evaluate time efficiency of the 
hybrid-QA method. 
Material and method: Accuracy of the model-based QA was determined by comparison of 
COMPASS calculated dose with Monte Carlo calculations for heterogeneous media. In total, 
330 intensity modulated radiation therapy (IMRT) treatment plans were evaluated based 
on the mean gamma index (GI) with criteria of 3%/3mm and classification of PASS (GI≤0.4), 
EVAL (0.4<GI<0.6) and FAIL (GI≥0.6). Agreement between model-based QA and 
measurement-based QA was determined for 48 treatment plans, and linac stability was 
verified for 15 months. Finally, time efficiency improvement of the hybrid-QA was 
quantified for four representative treatment plans. 
Results: COMPASS calculated dose was in agreement with Monte Carlo dose, with a 
maximum error of 3.2% in heterogeneous media with high density (2.4 g/cm3). Hybrid-QA 
results for IMRT treatment plans showed an excellent PASS rate of 98% for all cases. Model-
based QA was in agreement with measurement-based QA, as shown by a minimal difference 
in GI of 0.03 ± 0.08. Linac stability was high with an average GI of 0.28 ± 0.04. The hybrid-
QA method resulted in a time efficiency improvement of 15 minutes per treatment plan QA 
compared to measurement-based QA. 
Conclusions: The hybrid-QA method is adequate for efficient and accurate 3D dose 
verification. It combines time efficiency of model-based QA with reliability of measurement-
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Radiotherapy treatment techniques like Intensity Modulated Radiation Therapy (IMRT) 
and Intensity Modulated Arc Therapy (IMAT) may result in complex dose distributions with 
numerous high dose gradient regions. These high dose gradients allow better sparing of 
organs at risk compared to 3D-CRT techniques [1,2] and demand appropriate quality 
assurance (QA) in terms of dose verification. Since conventional 2D-based QA-techniques 
(e.g. with film or detector arrays) are reported to be less sensitive to high dose gradients 
[3,4], new QA-techniques are needed.  
Recently, IMRT-QA techniques have been developed to verify a dose distribution in 3D 
in a patient CT-data set based on either a pre-treatment dose calculation (model-based QA) 
[5,6], a pre-treatment dose reconstruction (measurement-based QA) [7,8] or with portal 
imaging during treatment allowing on-line verification [9]. As on-line verification QA 
methods generally involve extensive analysis procedures that require profound in-house 
expertise, pre-treatment measurement-based QA is still very popular and is considered in 
many radiotherapy centers as the standard. 
Since pre-treatment measurement-based QA is time consuming, the already limited 
personnel and practical access to the linear accelerator (linac) threatens to impose practical 
limitations on QA needed for modern treatment techniques. Therefore, time efficient QA is 
essential to keep the required level of QA in pace with the increasing number of treatment 
plans that need 3D-QA. 
A tempting solution to achieve a more time efficient QA is to switch from 
measurement-based QA to model-based QA. The consequence of this switch in QA-method 
is that verification of correct data transfer of the treatment plan to the linac is not included, 
nor the effect of incorrect linac output, leaf settings and gantry/collimator angle, i.e. linac 
behavior. However, if these verifications can be handled in other ways, the question is 
justified whether all or just a representative part of the treatment plans needs to be verified 
by a time consuming measurement-based QA. In addition, Olson et. al. showed that for the 
vast majority of treatment plans (>99.5%), no dose delivery error occurs implying the 
possibility of less measurement-based QA [10].  
In this study, a combination of model-based QA and measurement-based QA; i.e. the 
hybrid-QA, was investigated to obtain a QA-method that combines time efficiency of dose 
calculations with reliability of measurements. The aim of this paper is to evaluate the 
hybrid-QA method for IMRT treatment plans. First, the accuracy of the model-based QA will 
be determined and second, the new hybrid-QA method will be evaluated in terms of 




Material and Method  
Model-based QA and measurement-based QA 
In this study, the COMPASS system (version 1.2, IBA Dosimetry, Schwarzenbruck, 
Germany) was used for the hybrid-QA method as it can perform both model-based QA and 
measurement-based QA. The COMPASS system is a QA-tool that can be used to determine 
3D dose deposition in a CT-data set independent from the treatment planning system (TPS). 
Based on water phantom measurements and linac specific parameters, multiple fluence 
models for various linacs can be configured and validated. The 3D dose deposition in patient 
CT is determined by either a dose calculation (model-based) or a dose reconstruction 
(measurement-based).  
The model-based dose calculation is based on a commissioned fluence model and a 
dose engine. According to treatment plan parameters obtained from the RT-plan, fluence is 
calculated and combined with the CT-data set to calculate a 3D dose deposition. 
The measurement-based dose reconstruction takes into account linac behavior by 
incorporating information of a 2D measurement obtained with an ionization chamber array 
(MatriXX, IBA Dosimetry). First, fluence is calculated according to treatment parameters 
similar to the model-based dose calculation. Second, a detector response is predicted and 
compared to the measured response. According to the difference between the predicted 
and measured response, the calculated fluence is corrected using a correction kernel 
[11,12]. Finally, the corrected fluence is used for dose calculation in the CT-data set. 
Recent published work compared the measurement-based dose calculation performed 
with the COMPASS system to film measurements and concluded that the measurement-
based dose calculation is adequate for dose verification of IMRT treatment plans [11–13]. 
However, verification of the model-based dose calculation for heterogeneous media is still 
the missing part for the introduction of the hybrid-QA method. Therefore, validation of the 
model-based dose calculation for heterogeneous media is needed to assess its accuracy and 
reliability for any specific indication and technique before the hybrid-QA method can be 
introduced. 
 
COMPASS model-based dose calculation verification 
COMPASS dose calculations were verified by comparison with Monte Carlo dose 
calculations and our clinical TPS (Pinnacle version 8.0h, Philips Radiation Oncology Systems, 
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created in BEAMnrc (version 2010) [14] and dose calculations were computed with 
DOSXYZnrc (version 2010) and validated against water phantom measurements. Six artificial 
CT phantoms were created with heterogeneities in a range from 0.0 to 2.4 g/cm3. Four 
phantoms consisted of 50x50x50 cm3 water with a 2.5 cm diameter cylinder of 0.0, 1.8, 2.0 
or 2.4 g/cm3 density, respectively, at 10 cm depth. The remaining two phantoms 
represented patient-like geometries; one simulated a lung geometry with a tumor inside 
(densities of 0.25, 1.0 and 1.2 g/cm3) and the other represented a hip geometry that 
included tumor and bone tissue (densities of 1.0, 1.2 and 1.8 g/cm3).  
 
Hybrid-QA 
The hybrid-QA method (figure 1) combined COMPASS calculated dose (model-based 
QA) and COMPASS reconstructed dose (measurement-based QA). In the model-based QA, 
TPS calculated dose was compared with COMPASS calculated dose as independent dose 
verification. In the measurement-based QA, the TPS calculated dose was compared with 
COMPASS reconstructed dose in order to include data transfer and linac behavior in the 
verification. Reliability of the hybrid-QA was evaluated by comparing model-based QA with 
measurement-based QA results for a selection of approved treatments. In addition, stability 
of linac IMRT delivery was verified by a monthly evaluation of a standard head and neck 





Overview of the hybrid-QA method. (a) All treatment plans are verified with a model-based QA. 
Whenever a treatment plan fails to pass clinical acceptance criteria, the physician was consulted 
whether the dose differences were still clinically acceptable. (b) A random selection of approved 
treatment plans (approximately 15%) was evaluated with a measurement-based QA to assess the 
agreement between the model-based QA and measurement-based QA. (c) A standard head and neck 




































The hybrid-QA method was evaluated clinically to determine the impact on the QA-
procedure in terms of reliability and time efficiency. In total, 330 IMRT treatment plans were 
evaluated with the hybrid-QA method over a time period of 15 months. The majority of 
treatment plans consisted of head and neck treatments (80%) and a subset consisted of 
prostate (10%) and other various indications (10%). All treatment plans were analyzed and 
classified with the gamma evaluation based on the work of Stock et. al. [15] and clinical 
experience of the department. For clarity reasons, only the mean gamma index (GI) was 
included in the manuscript. We found the mean GI to be most representative for verification 
of a 3D dose distribution. The mean GI was classified into PASS (GI≤0.4), EVAL (0.4<GI<0.6) 
or FAIL (GI≥0.6) with criteria of 3%/3mm for the hot area (50% of the prescribed dose or 
higher). A mean GI below 0.6 (containing both PASS and EVAL) was accepted for treatment. 
The EVAL criterion was introduced as an extra level of evaluation to obtain a more sensitive 
QA-procedure. 
Reliability of the hybrid-QA method was evaluated by assessing the agreement 
between model-based QA and measurement-based QA for 48 treatment plans. Treatment 
plans in the PASS category were selected randomly (43 in total) and all treatment plans in 
the EVAL or FAIL category accepted for treatment were selected (five and zero respectively). 
In addition, stability of the linac was verified over a time period of 15 months. 
Time efficiency of the hybrid-QA method was evaluated by quantification of the 
average work load and linac time based on four representative head and neck IMRT 
treatment plans for the model-based QA, the measurement-based QA and the hybrid-QA 
method. The work load was grouped into three phases; preparation, execution and 
evaluation. First, the time needed to select the treatment plan and to load the data was 
determined (preparation phase). Second, the time needed to obtain a 3D dose distribution, 
and in case of the measurement-based QA, the time needed to attach and align the detector 
array to the linac and delivery of the treatment plan was determined (execution phase). 
Third, the time needed to compare and evaluate the dose distributions of the COMPASS 
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COMPASS dose calculation verification 
COMPASS calculated dose in 
heterogeneous media was in agreement 
with Monte Carlo dose calculations. 
COMPASS calculated a slightly higher dose in 
comparison to Monte with a maximum 
difference of 2.5% (for the secondary build-
up region), 1.5%, 2% and 3.2% for densities 
of 0.0, 1.8, 2.0 and 2.4 g/cm3 respectively. 
Pinnacle calculated a lower compared to 
Monte with a maximum difference of 7% for 
2.4 g/cm3 (figure 2). Furthermore, COMPASS 
calculated dose and Pinnacle calculated dose 
in patient-like phantoms consisting of 
materials with densities of 0.25 (lung), 1.0 
(tissue), 1.2 (tumor) and 1.8 (bone) g/cm3 
agreed with Monte Carlo calculated dose, as 
shown by dose differences well below 3% 
(see example in figure 3). In addition, 
secondary build-up effects at density 
transitions were accurately modeled. 
 
Figure 3:  
Comparison of COMPASS, Pinnacle and Monte 
Carlo calculated depth dose curve in a lung 
phantom with densities of 0.25 (lung), 1.00 
(tissue) and 1.20 (tumor) g/cm3 (shown in 
insert). Secondary build-up effects are visible at 
-12 cm (entrance of ‘tumor)’ and -2 cm 
(entrance of ‘mediastinum’). 
 
  
Figure 2:  
Comparison of COMPASS, Pinnacle and 
Monte Carlo calculated depth dose curves 
(top) and dose profiles (bottom) in a water 
phantom with a 2.5 cm diameter cylinder of 





All treatment plans 
verified by the model-
based QA (330) were 
accepted for treatment, 
indicating correct Pinnacle 
dose calculation (figure 4). 
Only five treatment plans 
resulted in an EVAL 
classification with dose 
differences in high density 
and/or build-up regions. 
The treatment plan with 
the highest GI (0.56) was an 
uncommon indication 
(skull) with over-travelled fields, resulting in dose differences up to 4% in the planned target 
volume. In addition, the planned target volume was located in the build-up region and 
included bone tissue with densities up to 2.5 g/cm3. 
All treatment plans that were selected for model-based QA and measurement-based 
QA (48) had acceptable QA results (either PASS or EVAL) for both methods, nevertheless, 
seven treatment plans were classified differently (figure 5). Four out of these seven 
treatment plans were classified PASS for the model-based QA and EVAL for the 
measurement-based QA and the remaining three treatment plans were classified EVAL for 
the model-based QA and PASS for the measurement-based QA. On average, the 
measurement-based QA resulted in a slightly higher GI with a mean difference of 0.03 ± 










Mean gamma index (GI) for 330 treatment plans with 325 PASS 
classifications (GI≤0.4) and five EVAL classifications (0.4<GI<0.6). 
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2.4 g/cm3 (figure 2). Furthermore, COMPASS 
calculated dose and Pinnacle calculated dose 
in patient-like phantoms consisting of 
materials with densities of 0.25 (lung), 1.0 
(tissue), 1.2 (tumor) and 1.8 (bone) g/cm3 
agreed with Monte Carlo calculated dose, as 
shown by dose differences well below 3% 
(see example in figure 3). In addition, 
secondary build-up effects at density 
transitions were accurately modeled. 
 
Figure 3:  
Comparison of COMPASS, Pinnacle and Monte 
Carlo calculated depth dose curve in a lung 
phantom with densities of 0.25 (lung), 1.00 
(tissue) and 1.20 (tumor) g/cm3 (shown in 
insert). Secondary build-up effects are visible at 
-12 cm (entrance of ‘tumor)’ and -2 cm 
(entrance of ‘mediastinum’). 
 
  
Figure 2:  
Comparison of COMPASS, Pinnacle and 
Monte Carlo calculated depth dose curves 
(top) and dose profiles (bottom) in a water 
phantom with a 2.5 cm diameter cylinder of 





All treatment plans 
verified by the model-
based QA (330) were 
accepted for treatment, 
indicating correct Pinnacle 
dose calculation (figure 4). 
Only five treatment plans 
resulted in an EVAL 
classification with dose 
differences in high density 
and/or build-up regions. 
The treatment plan with 
the highest GI (0.56) was an 
uncommon indication 
(skull) with over-travelled fields, resulting in dose differences up to 4% in the planned target 
volume. In addition, the planned target volume was located in the build-up region and 
included bone tissue with densities up to 2.5 g/cm3. 
All treatment plans that were selected for model-based QA and measurement-based 
QA (48) had acceptable QA results (either PASS or EVAL) for both methods, nevertheless, 
seven treatment plans were classified differently (figure 5). Four out of these seven 
treatment plans were classified PASS for the model-based QA and EVAL for the 
measurement-based QA and the remaining three treatment plans were classified EVAL for 
the model-based QA and PASS for the measurement-based QA. On average, the 
measurement-based QA resulted in a slightly higher GI with a mean difference of 0.03 ± 










Mean gamma index (GI) for 330 treatment plans with 325 PASS 
classifications (GI≤0.4) and five EVAL classifications (0.4<GI<0.6). 





Monthly verification of 
the standard head and neck 
IMRT treatment plan with 
measurement-based QA 
resulted in an average GI of 
0.28 ± 0.04, indicating 
stable IMRT delivery by the 
linac over a period of 15 
months. 
Average work load for 
the hybrid-QA was derived 
from the work load of the 
model-based QA and 
measurement-based QA 
(table 1). Preparation time was equal for all three QA-procedures. However, execution time 
for the hybrid-QA method was substantially lower in comparison to the measurement-
based QA as only a selection of treatment plans (approximately 15%) were executed with a 
measurement-based QA. Vice versa, execution of a selection of treatment plans using the 
measurement-based QA resulted in a higher execution time for the hybrid-QA method 
compared to the model-based QA. Evaluation time of the hybrid-QA method was slightly 
higher in comparison to the model-based QA and measurement-based QA due to the re-
evaluation of a selection of treatment plans. By switching from the standard measurement-
based QA to the hybrid-QA, an efficiency improvement of 15 minutes per treatment plan 
was obtained due to decrease of linac time required for QA purposes.  
 
Table 1: 
Average work load per treatment plan in minutes based on four representative head and neck IMRT 
treatment plans if no problems occur and performed by an experienced user. Measurements for the 
four treatment plans were completed in one single measurement session. 
Work load (min) Model-based QA Measurement-based QA Hybrid-QA 
Preparation 2 2 2 
Execution 2 22 6 
Evaluation 6 6 7 




Figure 5:  
Model-based QA and measurement-based QA agreed for 41 
treatment plans (●) and resulted in different classification for 
seven treatment plans (▲). All 48 treatment plans were 





In this study, we evaluated the hybrid-QA method which combines model-based QA 
with measurement-based QA. Our results showed that the accuracy of the COMPASS dose 
calculation used in model-based QA is adequate for 3D dose verification. Only for 
heterogeneous media with densities above 2.0 g/cm3, dose differences just exceeded 
clinical acceptance criteria. Moreover, within the high density regions, COMPASS 
overestimated and Pinnacle underestimated the dose which resulted in an overestimation 
of the GI determined by the hybrid-QA method. Nevertheless, dose differences were 
clinically acceptable as the overestimation is confined to high density regions of limited size 
within the patient and all evaluated treatment plans were accepted for treatment. 
The hybrid-QA method seems reliable as the differences observed between model-
based QA and measurement-based QA had no effect on the clinical decision to accept or 
reject the treatment plan. All 48 treatment plans were accepted for treatment based on 
both evaluations. In absolute values, the average differences between the model-based QA 
and measurement-based QA were well below 0.5%/0.5mm, which will have little effect on 
the classification of the treatment plan. When outcomes of the hybrid-QA method obtained 
by either the model-based QA or measurement-based QA come close to the cut-off point 
of the PASS and EVAL classification, it will have no effect on the clinical outcome and need 
no extra evaluation, whereas outcomes which come close to the cut-off point of EVAL and 
FAIL need extra evaluation for both the model-based QA and the measurement-based QA. 
By determining the agreement between model-based QA and measurement-based QA for 
a random selection of approved treatment plans, the hybrid-QA method verifies whether 
results for model-based QA are still representative for measurement-based QA results. If 
differences between model-based QA and measurement-based QA do occur, extra analysis 
of the treatment plan and/or linac is necessary to determine the origin of the observed 
difference. In addition, monthly verification of the standard head and neck IMRT treatment 
plan showed stable IMRT treatment delivery by the linac strengthening the reliability of the 
hybrid-QA method. 
We found that the introduction of the hybrid-QA method substantially decreased the 
required linac time, improving the time efficiency of the departments QA-procedure. And 
because model-based QA and measurement-based QA are in agreement for randomly 
selected treatment plans, all model-based QA outcomes in this study (330 treatment plans) 
would most likely be unaffected when performed with the measurement-based QA 
underlining the possibility of introducing the hybrid-QA method for pre-treatment 
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has to be noted that the initial time effort needed to commission the QA-system has not 
been included in the analyses. On the other hand, this time is averaged out when 
performing the hybrid-QA method for a large amount of treatment plans. Second, the 
evaluation has been performed by an experienced user. The lack of experience with the 
hybrid-QA method can affect efficiency improvement, but as this learning curve is a 
transient effect it will eventually have little effect on the efficiency improvement. Third, the 
extra time needed to evaluate a treatment plan containing relevant dose differences has 
not been included in the analyses. Nevertheless, research has shown that no dose delivery 
error occurred in 99.5% of the treatment plans [10]. Therefore, a substantial time efficiency 
improvement is to be expected when switching from measurement-based QA to the hybrid-
QA method. 
A consequence of the transition from measurement-based QA to the hybrid-QA 
method is that correct data transfer of the treatment plan to the linac is only checked for a 
selection of treatment plans. And although many of these checks can be covered by safety 
measures, such as interrupts on faulty linac dosimetry and checks on the treatment plans 
stored in the database, errors can still occur. We find this has to be compensated for. Log 
files can be appropriate, as it allows verification of data transfer and actual linac delivery 
parameters like MLC positioning [16]. Whereas log files allow an indirect verification of 
delivered dose, alternatively, actually delivered dose information can be obtained by the 
introduction of measurements during patient treatment (on-line) with EPID dosimetry or a 
transmission detector [9,12,17,18] Implementation of these techniques is suggested to 
complement the current hybrid-QA method to allow dose verification for every treatment 
plan prior to the treatment course for independent dose verification and during the 
treatment course for verification of actual treatment delivery. 
For this study, classification of the QA-results was determined by the mean gamma 
index for the hot area. The suitability of the mean gamma index for 3D dose verification of 
IMRT treatment plans has not been investigated thoroughly and research has shown that 
the gamma evaluation has its limits in terms of resolution [19] and prediction power for 
clinical relevance [20]. Evaluation based on dose volume histograms (DVH) may be an 
alternative since it allows the physicist and/or physician to accept or reject a treatment plan 
based on delivered dose to the organs at risk and/or tumor [7,21]. Nevertheless, we used 
the mean gamma index because it takes into account both dose difference and distance to 
agreement. In addition, the mean gamma index is widely accepted in the field of 




Our study showed that the hybrid-QA method is reliable and allows the user to verify a 
large number of complex treatment plans maintaining the necessary accuracy. In addition, 
the hybrid-QA method could be a universal method as it may be implemented for, and 
combined with different QA-tools. Where the model-based QA could be performed by 
Monte Carlo calculations, the measurement-based QA could be performed with EPID-
dosimetry. Therefore, the hybrid-QA method may be implemented in many radiotherapy 
departments combined with different QA-tools. 
 
Conclusion 
Accuracy of the hybrid-QA method is adequate for 3D dose verification purposes. 
Moreover, model-based QA and measurement-based QA are in agreement underlining the 
possibility of performing less measurement-based QA as is done for the hybrid-QA method. 
Introduction of the hybrid-QA method reduced linac time substantially compared to 
measurement-based QA allowing the user to verify a large number of complex treatment 
plans improving time efficiency of the QA-procedure. In addition, the hybrid-QA method 
may be implemented for, and combined with different QA-tools. Therefore, we conclude 
that the hybrid-QA method is a reliable, time efficient and universal method for 3D dose QA 
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FOR INTENSITY MODULATEDRADIOTHERAPY 
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Chapter 6
Evaluation of DVH-based treatment plan 
verification in addition to gamma passing rates 
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Abstract 
Background and purpose: Treatment plan verification of Intensity Modulated 
Radiotherapy (IMRT) is generally performed with the gamma index (GI) evaluation 
method, which is difficult to extrapolate to clinical implications. Incorporating Dose 
Volume Histogram (DVH) information can compensate for this. The aim of this study was 
to evaluate DVH-based treatment plan verification in addition to the GI evaluation method 
for head and neck IMRT.  
Material and method: Dose verifications of 700 subsequent head and neck cancer IMRT 
treatment plans were categorised according to gamma and DVH-based action levels. 
Fractionation dependent absolute dose limits were chosen. The results of the gamma- and 
DVH-based evaluations were compared to the decision of the medical physicist and/or 
radiation oncologist for plan acceptance. 
Results: Nearly all treatment plans (99.7%) were accepted for treatment according to the 
GI evaluation combined with DVH-based verification. Two treatment plans were re-
planned according to DVH-based verification, which would have been accepted using the 
evaluation alone. DVH-based verification increased insight in dose delivery to patient 
specific structures increasing confidence that the treatment plans were clinically 
acceptable. Moreover, DVH-based action levels clearly distinguished the role of the 
medical physicist and radiation oncologist within the Quality Assurance (QA) procedure.  
Conclusion: DVH-based treatment plan verification complements the GI evaluation 
method improving head and neck IMRT-QA.  
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Results: Nearly all treatment plans (99.7%) were accepted for treatment according to the 
GI evaluation combined with DVH-based verification. Two treatment plans were re-
planned according to DVH-based verification, which would have been accepted using the 
evaluation alone. DVH-based verification increased insight in dose delivery to patient 
specific structures increasing confidence that the treatment plans were clinically 
acceptable. Moreover, DVH-based action levels clearly distinguished the role of the 
medical physicist and radiation oncologist within the Quality Assurance (QA) procedure.  
Conclusion: DVH-based treatment plan verification complements the GI evaluation 
method improving head and neck IMRT-QA.  
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Introduction 
Radiotherapy pre-treatment plan verification is an important aspect in Quality 
Assurance (QA) of intensity modulated radiotherapy (IMRT) [1]. In literature, various dose 
verification techniques suitable for patient specific QA have been described [2–5]. 
Commonly, patient specific QA is performed by a physicist who accepts or rejects a 
treatment plan based on QA results.  
From a clinical point of view, QA results used for dose verification purposes should 
focus on detrimental dose differences as these ultimately determine whether or not a 
treatment plan is acceptable for treatment. Detrimental effects can be caused by under 
dosage and/or over dosage in patient specific structures [6–8]. The current standard 
method for IMRT dose verification is the gamma index (GI) evaluation method, which 
combines spatial information and dose differences for a 2D plane or a 3D volume [9,10]. 
Nevertheless, the GI evaluation lacks information on dose to patient specific structures 
making it difficult to extrapolate gamma passing rates to clinical implications [11]. This is 
underlined by research which shows that gamma passing rates correlate weakly with dose 
differences in target volumes and Organs At Risk (OARs) [12–14]. Furthermore, the GI 
evaluation has limited accuracy in areas with high dose gradients [15]. To overcome these 
limitations, Dose Volume Histogram (DVH) information can be incorporated within the QA 
procedure, in addition to gamma passing rates. This should result in a more complete QA 
methodology as it consists of a global dose verification using gamma passing rates, and 
allows verification of detrimental dose differences for patient specific structures. 
In current practice, the physicist is responsible for the entire QA procedure, and the 
radiation oncologist is responsible for the treatment plans used for treatment. By 
incorporating DVH-information in the QA procedure, involvement of the radiation 
oncologist is required to determine the relevance of observed dose differences between 
the planned dose and the QA-dose from a clinical point of view. This shift in responsibility 
for accepting or rejecting a treatment plan needs to be taken into account within the QA 
procedure, and be reflected in applicable criteria, without ambiguity in responsibility. The 
use of gamma passing rates can be found in literature [16] but a consensus on DVH-based 
action levels is still lacking.  
The aim of this study was to evaluate DVH-based treatment plan verification in 
addition to gamma passing rates for head and neck IMRT, and to assess the consequences 
within the QA procedure. 
 
    
Material and Method  
Study population 
To evaluate DVH-based dose verification, a population analysis was performed for 700 
subsequent head and neck IMRT treatment plans made for clinical treatment from 
December 2009 to November 2012 on four Elekta SLi-15 machines and one Elekta Synergy 
machine. Treatment plans were created with Pinnacle (version 8.0 and 9.0, Philips 
Radiation Oncology Systems, Madison USA), on a 4x4x2mm3 dose grid. QA was performed 
with the COMPASS system (version 2.1, IBA Dosimetry, Schwarzenbruck, Germany). 
 
QA-procedure 
QA was performed following our previously described hybrid-QA procedure consisting 
of a combination of calculation-based QA for all treatment plans and measurement-based 
QA for a selection of treatment plans [17]. For the calculation-based QA, dose calculations 
performed by the treatment planning system (TPS) were compared to dose calculations 
performed by the QA-system (QA-dose). For the measurement-based QA, TPS-dose was 
compared to QA-dose obtained by a dose reconstruction from measurements. To verify 
the calculation-based QA result, measurement-based QA results were obtained for a 
random selection of treatment plans and for treatment plans failing the calculation-based 
QA. In a recent study, measurement-based QA results were found to be comparable to 
film dosimetry results [18]. Treatment plans were categorised according to standard pre-
defined action levels used in the clinic for the GI evaluation method. For this study, an 
additional categorisation was developed according to DVH-based criteria. 
 
Gamma-based action levels 
Gamma passing rates for the composite dose were obtained by a global 3D gamma 
analysis (3%/3mm) categorised according to the GI for the hot area (volume receiving 50% 
or more of the prescribed dose) in the patient CT based on Stock et. al. [16] combined 
with clinical experience of the department. The GI was categorised into ‘PASS’ (accept for 
treatment), ‘EVAL’ (evaluate by the medical physicist) or ‘FAIL’ (reject for treatment). 
Criteria for the mean gamma were classified into PASS (GI ≤ 0.4), EVAL  (0.4 < GI < 0.6), 
and FAIL (GI ≥ 0.6), and the percentage of voxels with a GI above one was classified into 
PASS (≤ 3.0%), EVAL (> 3.0% and <7.5%), and FAIL (≥ 7.5%). A QA result was considered 
unjustified when a treatment plan was categorised as FAIL but accepted for treatment by 
the medical physicist.  
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DVH-based action levels 
DVH-information was gathered for the Planning Target Volume (PTV) and seven types 
of OAR; brain, eyes, lenses, cochlea, parotid glands, submandibular glands, and spinal 
cord. The PTV was a therapeutic or a prophylactic volume; i.e., PTV-therapeutic or PTV-
prophylactic. The mean dose (Dmean) was determined for all structures, and the maximum 
dose (D1) for 1.0% of the volume was determined for the PTV, eyes, spinal cord, and brain 
(0.1% in case of the brain volume, D0.1). The minimum dose (D99) for 99% of the volume 
was determined for the PTV’s. 
 
Table 1:  
DVH-based action levels for nine structure types with classification ‘PASS’ (accept for treatment), 
‘EVALMP’ (evaluate by medical physicist), ‘EVALRO’ (evaluate by radiation oncologist), and ‘EVALMP+RO’ 
(evaluate by medical physicist and radiation oncologist) based on dose differences (Ddiff), and 
absolute dose thresholds (D). Absolute dose levels were set for a fractionation scheme consisting of 
35 fractions and adapted in case of a different fractionation. 
Structure Dose 
parameter PASS EVALMP EVALRO EVALMP+RO 
PTV-therapeutic / Dmean Ddiff ≤ 2.0% 2.0% < Ddiff < 2.5% - Ddiff ≥ 2.5% 
PTV-prophylactic D99 Ddiff ≤ 3.0% 3.0% < Ddiff < 5.0% - Ddiff ≥ 5.0% 
 D1 Ddiff ≤ 3.0% 3.0% < Ddiff < 5.0% - Ddiff ≥ 5.0% 
Lens Dmean Ddiff ≤ 2.0% 2.0% < Ddiff < 2.5% - Ddiff ≥ 2.5% 
Eye Dmean Ddiff ≤ 2.0% 2.0% < Ddiff < 2.5% - Ddiff ≥ 2.5% 
 D1 Ddiff ≤ 3.0% 3.0% < Ddiff < 5.0% - Ddiff ≥ 5.0% 
Parotid gland Dmean Ddiff ≤ 2.0% 2.0% < Ddiff < 2.5% - Ddiff ≥ 2.5% 
Submandibular 
gland Dmean Ddiff ≤ 2.0% 2.0% < Ddiff < 2.5% - Ddiff ≥ 2.5% 
Cochlea Dmean Ddiff ≤ 4.0%  Ddiff > 4.0% D > 53 Gy Ddif >4.0% & D>53Gy 
Spinal cord D1 Ddiff ≤ 3.0% Ddiff > 3.0% D > 56 Gy Ddiff>3.0% &D>56Gy 
Brain D0.1 Ddiff ≤ 3.0% Ddiff > 3.0% D > 63 Gy Ddiff>3.0% &D>63Gy 
 
Differences between TPS-dose and QA-dose were evaluated by the medical physicist 
and/or radiation oncologist according to pre-defined action levels (Table 1). To distinguish 
the role of the medical physicist and radiation oncologist, DVH-based QA results were 
categorised into; ‘PASS’ (accept for treatment), ‘EVALMP’ (evaluate by the medical 
physicist), ‘EVALRO’ (evaluate by the radiation oncologist), and ‘EVALMP+RO’ (evaluate by the 
medical physicist and radiation oncologist). Cutoff values for a 35 fractionation scheme 
were based on a consensus of our head and neck radiation oncologist group based on 
their expert opinion combined with QUANTEC data [7]. Absolute dose levels were adapted 
in case of a fractionation scheme different from 35 fractions.  
    
In contrast to the gamma evaluation, no ‘FAIL’ was defined because all observed dose 
differences failing the PASS criteria had to be evaluated by the medical physicist and/or 
radiation oncologist. If for instance the dose in an OAR exceeded the PASS criteria but 
could not be reduced without compromising target coverage, the radiation oncologist 
could decide to accept the treatment plan for treatment. Therefore, EVAL classifications 
were found to be more suitable. 
For individual patient QA, treatment plans categorised as EVALMP were found 
acceptable for treatment. The EVALMP category was used in addition to evaluate the dose 
accuracy of the TPS by performing a population anlysis. A QA result was considered 





Based on the population analysis, only two out of 700 (0.3%) treatment plans were 
rejected for treatment. Both treatment plans, which were missed by the GI evaluation, 
were detected by DVH-based action levels. Both treatment plans were rejected based on 
an over dosage in the PTV-therapeutic. For the first treatment plan, the tumour was 
situated close to the patient outline. For correct dose delivery, additional build-up 
material was used. Due to standard planning margins used for the PTV, part of the PTV 
was situated inside the additional build-up material, thus outside the patient outline. In 
contrast to the QA-system, the TPS calculated no dose in the area outside the patient 
outline. To fulfil the planning-objectives for Dmean of the PTV, the TPS optimiser increased 
the dose resulting an over dosage. By lowering the air-threshold for dose calculations from 
0.6 g/cm3 to 0.1 g/cm3 for the TPS during re-planning, the TPS also calculated dose in the 
build-up material resulting in avoidance of erroneous optimisation, and a better 
agreement with the QA-system. The adapted treatment plan with an adjusted air 
threshold for dose calculations was accepted for treatment. For the second treatment 
plan, the iso-center was positioned outside the PTV-therapeutic, approximately 6 cm 
cranially, resulting in over-travelled fields with less accurate dose calculations by the TPS. 
This effect was corrected for by re-positioning of the iso-center during re-planning.  
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Figure 1:  
QA results of 700 treatment plans for the DVH-based action 
levels of nine delineated structure types categorised into ‘PASS’ 
(accept for treatment), ‘EVALMP’ (evaluate by the medical 
physicist), ‘EVALRO’ (evaluate by radiation oncologist), and 
‘EVALMP+RO’ (evaluate by medical physicist and radiation 
oncologist) for the mean dose (Dmean), minimum dose (D99), and 












































Eye Spinal cord Brain
EVALMP+RO (n) 31 5 20 2 1 9 7 15 0 12 0 1 0 1
EVALRO (n) 0 0 0 0 0 0 6 0 0 0 0 0 5 26
EVALMP (n) 59 28 23 4 9 13 5 21 6 63 28 10 5 4





Gamma-based action levels 
For the GI evaluation, three (0.4%) treatment plans failed the mean GI, and nine 
(1.3%) treatment plans failed the GI>1 criteria. All treatment plans failing the GI criteria 
showed at least one or more EVAL classifications for the DVH-based action levels, but 
were found not to be clinically relevant as the observed dose differences were not 
expected to affect treatment outcome. Therefore, none of the treatment plans were 
rejected for treatment, and considered to be unjustified QA results for the gamma 
evaluation. 
 
DVH-based action levels 
The population analysis showed that the PTV-therapeutic, cochlea, and brain resulted 
in the lowest PASS rates (Figure 1). For the PTV-therapeutic, and cochlea this 
corresponded to a relatively large spread in the dose differences as shown in the dose 
statistics (Table 2). In general, calculation-based QA performed with the QA-system 
resulted in a slightly higher dose in comparison to TPS dose calculations with an average 
difference mostly less than 1 Gy. Calculation-based QA results were considered 
comparable to measurement-based QA result as observed average dose differences for all 
delineated structures, 
except for D0.1 for the 
brain which is based on a 
very small fractional 
volume, were within 0.6 
Gy and 0.8%. A 
representative selection 
of delineated structures 
is presented in Table 3. 
Furthermore, DVH-based 
action levels could clearly 
distinguish the role of the 
medical physicist and 
radiation oncologist 
within the QA procedure 
in evaluating a treatment 
plan.  
    
Table 2:  
QA results for nine delineated structure types with frequency (n), dose statistics and dose difference 












therapeutic Dmean 700 63.7 ± 9.5 64.1 ± 9.6 0.7 ± 0.7 1.1 ± 1.2 
 D99 699 59.0 ± 10.3 59.8 ± 9.7 0.8 ± 3.9 1.2 ± 6.4 
 D1 700 66.8 ± 10.0 67.8 ± 10.1 1.0 ± 0.9 1.5 ± 1.4 
PTV-prophylactic Dmean 513 59.7 ± 4.9 60.3 ± 4.9 0.6 ± 0.6 0.9 ± 1.0 
 D99 512 50.6 ± 3.3 50.9 ± 3.4 0.3 ± 0.7 0.4 ± 1.1 
 D1 513 69.5 ± 5.7 70.4 ± 5.8 0.9 ± 0.7 1.3 ± 1.1 
Lens Dmean 1363 3.0 ± 7.0 3.1 ± 7.2 0.0 ± 0.5 0.1 ± 0.8 
Eye Dmean 1368 3.6 ± 7.6 3.3 ± 7.7 -0.2 ± 0.4 -0.3 ± 0.6 
 D1 1369 5.8 ± 10.9 5.6 ± 10.9 -0.2 ± 0.6 -0.4 ± 1.0 
Parotid gland Dmean 1154 26.9 ± 16.8 27.0 ± 17.1 0.1 ± 0.5 0.1 ± 0.8 
Submandibular 
gland Dmean 490 39.5 ± 24.8 39.7 ± 25.1 0.2 ± 0.7 0.3 ± 1.0 
Cochlea Dmean 101 26.8 ± 17.4 27.8 ± 18.2 1.0 ± 1.3 1.5 ± 1.9 
Spinal cord D1 666 38.9 ± 12.8 39.2 ± 13.0 0.3 ± 0.7 0.5 ± 1.0 
Brain D0.1 247 34.5 ± 21.3 34.7 ± 21.9 0.2 ± 0.9 0.3 ± 1.5 
 
PTV-therapeutic 
The population analysis of the PTV showed that for the PTV-therapeutic, 31 (4.4%) 
treatment plans were categorised as EVALMP+RO and needed to be evaluated by the 
medical physicist and radiation oncologist together. Furthermore, D99 of the PTV-
therapeutic showed a relatively large dose spread (3.9 Gy and 6.4%). Re-evaluation of ten 
worst cases showed that dose differences were situated in the build-up area, and in 
regions with high density bone such as the skull and lower jaw (>2.0 g/cm3). Lowering the 
air threshold in our TPS from 0.6 g/cm3 to 0.1 g/cm3 resulted in a better agreement 
between the TPS and the QA-system. Dose increase for the QA-system calculations for 
high density bone was confirmed by Monte Carlo calculations. The dose calculation 
differences between the TPS and QA-system for high density bone were found acceptable. 
Two out of 31 EVALMP+RO classifications resulted into a re-planning of the treatment plan 
and were considered to be justified QA results. 
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Figure 1:  
QA results of 700 treatment plans for the DVH-based action 
levels of nine delineated structure types categorised into ‘PASS’ 
(accept for treatment), ‘EVALMP’ (evaluate by the medical 
physicist), ‘EVALRO’ (evaluate by radiation oncologist), and 
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therapeutic showed a relatively large dose spread (3.9 Gy and 6.4%). Re-evaluation of ten 
worst cases showed that dose differences were situated in the build-up area, and in 
regions with high density bone such as the skull and lower jaw (>2.0 g/cm3). Lowering the 
air threshold in our TPS from 0.6 g/cm3 to 0.1 g/cm3 resulted in a better agreement 
between the TPS and the QA-system. Dose increase for the QA-system calculations for 
high density bone was confirmed by Monte Carlo calculations. The dose calculation 
differences between the TPS and QA-system for high density bone were found acceptable. 
Two out of 31 EVALMP+RO classifications resulted into a re-planning of the treatment plan 
and were considered to be justified QA results. 
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Figure 2:  
A typical patient case of which the cochlea 
was situated in a high dose gradient. A small 
shift in dose deposition resulted in a difference 
of 5.1% for Dmean of the cochlea between the 
TPS (57.1 Gy) and QA-system (60.6 Gy) for a 
4x4x2 mm3 dose grid. Adjustment of the dose 
grid to 2x2x2mm3 had little effect on the TPS-
dose (57.5 Gy) and QA-dose (60.1 Gy). The 
treatment plan was categorised EVALMP+RO as 
the absolute dose threshold of 53 Gy was 




Table 3:  
Dose differences for measurement-based QA and calculation-based QA for a selection of four 
delineated structure types with frequency (n), and dose difference (measurement-based QA – 
calculated-based QA).  Indicated values are the average ± one standard deviation over all the 
treatment plans.  
Structure  Dose parameter  n  Difference (Gy)  Difference (%)   
PTV-therapeutic  Dmean  88  -0.2 ± 0.6 -0.3 ± 0.9   
Cochlea  Dmean 15  -0.3 ± 0.9  -0.5 ± 1.4   
Spinal cord  D1  88  -0.4 ± 0.9  -0.6 ± 1.4   
Brain  D0.1 18  -0.9 ± 1.0  -1.2 ± 1.6   
 
Cochlea 
In total, six treatment plans were 
categorised as EVALRO, and seven as 
EVALMP+RO. All 13 treatment plans were 
accepted for treatment, thus QA results 
were considered unjustified. The dose 
statistics of the cochlea showed a 
relatively large systematic offset Dmean 
(1.5% ± 1.9%) which contributed to the 
relatively low PASS rate (<85%). Analysis 
showed that for the worst cases, the 
cochlea was situated in a high dose 
gradient up to 4Gy/mm. The 
combination of the relatively small 
volume (approximately 0.05cm3) of the 
cochlea combined with high dose 
gradients increased the dose differences 
between the TPS and the QA-system 
(1.0 Gy ± 1.3 Gy). Figure 2 shows a 
typical case of a cochlea situated in a 
high dose gradient. Due to a small shift 
in the dose, the differences between the 
TPS-dose dose and QA-dose increased. 
 
  





















































































Q -do (Gy)-do (Gy)
Spinal cord 
Five treatment plans categorised as EVALRO were considered unjustified QA results as 
these treatment plans were found acceptable for treatment by the radiation oncologist 
after evaluation. Moreover, at 50 Gy a clear cut off point was seen which was due to 
planning objectives used in the clinic (Figure 3). The dose differences between the TPS-
dose and QA-dose (0.5% ± 1.0%) had no negative effect on the QA results as the margin 
between the planning objectives and the DVH-based action level was sufficient. 
 
Figure 3:  
DVH-based action levels 
for Dmean of the PTV-
therapeutic (top left), 
Dmean of the cochlea (top 
right), D1 of the spinal 
cord (bottom left), and 
D0.1 of the brain (bottom 
right). Calculated dose 
was normalised to a 
fractionation schedule 
with 35 fractions. Action 
levels were categorised 
into ‘PASS’ (accept for 
treatment), ‘EVALMP’ 
(evaluate by medical physicist), ‘EVALRO‘ (evaluate by radiation oncologist), and ‘EVALMP+RO‘ 
(evaluate by medical physicist and radiation oncologist).  
 
Brain 
In total, 26 treatment plans were categorised as EVALRO and one treatment plan was 
categorised as EVALMP+RO. The treatment plan categorised as EVALMP+RO consisted of an 
uncommon indication (skull) with over-travelled fields. In this situation the PTV was 
situated in the build-up region consisting of high density bone (2.5 g/cm3). After 
evaluation, the treatment plan was accepted for treatment by the medical physicist and 
radiation oncologist and therefore considered to be an unjustified QA result. The 26 
treatment plans categorised as EVALRO were considered unjustified QA results as well 
because they were accepted for treatment by the radiation oncologist as the dose 
differences were considered not to be clinically relevant. 
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Five treatment plans categorised as EVALRO were considered unjustified QA results as 
these treatment plans were found acceptable for treatment by the radiation oncologist 
after evaluation. Moreover, at 50 Gy a clear cut off point was seen which was due to 
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dose and QA-dose (0.5% ± 1.0%) had no negative effect on the QA results as the margin 
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Brain 
In total, 26 treatment plans were categorised as EVALRO and one treatment plan was 
categorised as EVALMP+RO. The treatment plan categorised as EVALMP+RO consisted of an 
uncommon indication (skull) with over-travelled fields. In this situation the PTV was 
situated in the build-up region consisting of high density bone (2.5 g/cm3). After 
evaluation, the treatment plan was accepted for treatment by the medical physicist and 
radiation oncologist and therefore considered to be an unjustified QA result. The 26 
treatment plans categorised as EVALRO were considered unjustified QA results as well 
because they were accepted for treatment by the radiation oncologist as the dose 
differences were considered not to be clinically relevant. 
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Discussion 
This study shows that the use of DVH-information for treatment plan verification of 
head and neck IMRT treatment plans complements the standard gamma evaluation, as 
two treatment plans were identified that needed a re-planning which would have been 
accepted for treatment when merely the GI evaluation had been used. DVH-based dose 
verification increases insight in dose delivered to patient specific structures allowing a 
treatment plan to be accepted or rejected based on clinically relevant dose differences. 
Moreover, DVH-based action levels introduced in this study clearly distinguished the roles 
of the medical physicist and radiation oncologist within the QA-procedure. However, as 
Zijtveld et. al. pointed out, DVHs lack spatial information. This can result in large dose 
differences in a relatively small volume, which can possibly have a clinical impact, to go 
undetected [19]. Furthermore, as not all anatomical structures are delineated, clinically 
relevant dose differences outside delineated structures can be missed. To overcome the 
lack of spatial information for DVH-based dose verification our initial dose verification 
procedure, the GI evaluation, was incorporated in the QA-procedure for this study. It is a 
widely accepted method and considered to be a powerful tool for dose verification 
purposes [10,16]. In addition, it allows a fast and accurate visual inspection of observed 
dose differences. Even so, it has to be noted that the sensitivity of the GI evaluation is 
affected by the size of the evaluated volume. The larger the volume, the less sensitive the 
GI evaluation is in detecting dose differences in small volumes. Therefore, for this study, 
only the hot area (volume receiving 50% or more of the prescribed dose) was evaluated by 
GI evaluation. An interesting alternative for future research could be the introduction of 
cut-off values based on the absolute volume with a GI above one. For this study, the dose 
to OARs outside the hot area was verified by the DVH-based dose verification, underlining 
the fact that DVH-based dose verification is complementary to gamma passing rates. 
The introduction of DVH-based treatment plan verification resulted in an increase in 
the number of treatment plans that needed to be re-evaluated (±10%), leading to some 
reduction in time efficiency of the QA-procedure. For this study, two important aspects 
contributed the most to this effect which could be compensated for. The first aspect 
contributing to the increase in treatment plans that needed to be re-evaluated originates 
from the selection of the action level verifying percentage dose differences for Dmean of the 
PTV. This was set to 2.5% and is somewhat strict resulting in multiple treatment plans to 
be re-evaluated even though they were found acceptable for treatment. In addition, the 
minor systematic dose difference between the TPS and QA-system (1.1%) increased the 
amount of treatment plans that needed to be re-evaluated even more. One can discuss 
    
 
 upon the selected criterion of 2.5% to be too sensitive as a minor adjustment would 
decrease the amount of unjustified QA results substantially. Nevertheless, adjustment of 
the criterion should be done with care to maintain correct error-detection of treatment 
plan verification. The second aspect contributing to the increase in treatment plans that 
needed to be re-evaluated originates from the patient characteristics. For multiple 
treatment plans, an OAR was situated close to the PTV resulting in a dose exceeding the 
fractionation dependent action levels (±5.0%). The dose exceeding the planning objectives 
was already accepted by the radiation oncologist prior to the QA-procedure, which in 
principle needed no re-evaluation unless the dose exceeded the percentage dose 
difference criteria. By taking this effect into account within the QA-procedure, less 
treatment plans will need to be re-evaluated resulting in less unjustified QA results.  
The population analysis increased insight in minor systematic dose differences in dose 
calculations between the TPS and QA-system for patient specific structures. These minor 
systematic dose differences may go undetected for individual patient QA and therefore 
should be accounted for when determining margins between planning objectives and 
DVH-based action levels. Furthermore, the population analysis showed dose calculation 
differences between the TPS and QA-system in the build-up area and in high dose 
gradients. The differences in the build-up area originated from the default settings of the 
TPS. For multiple treatment plans, the tumour was situated close to the patient outline. 
For correct dose delivery, additional build-up material was used for these patients. The 
use of standardised planning margins for the PTV resulted in part of the PTV to be situated 
inside the additional build-up material, outside the patient outline. In comparison to the 
QA-system, the TPS calculated no dose outside the patient outline. To fulfil the planning-
objectives for Dmean of the PTV, the TPS optimiser increased the dose resulting in large 
dose differences during evaluation. This effect was compensated for by reducing the air-
threshold for dose calculations of the TPS. The differences in high dose gradients were 
attributed to less accurate modelling of the penumbra region, and found acceptable for 
this study. To minimise unjustified QA results, commissioning of both the TPS and QA-
system is conditional in IMRT-QA. After commissioning, a powerful tool suitable to verify 
correct error-detection in patient specific QA can be obtained by receiver-operating-
analyses [20,21]. In a previous study, we performed a similar approach and concluded the 
QA-system used for this study to be suitable for 3D dose verification purposes [22]. 
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To ensure reliability of calculation-based QA results, a reference is essential. For this 
study, the hybrid-QA method was applied which regularly verifies calculation-based QA 
results with measurements. Even though our previous study, and results of this study, has 
shown that calculation-based QA results are comparable to measurement-based QA 
results [17], in our opinion, observed calculation based dose differences which can have 
unwanted clinical consequences should be verified by a measurement-based QA. This 
enhances reliability of the QA result, which increases the confidence of the medical 
physicist and/or radiation oncologist in deciding whether or not the treatment plan is 
acceptable for treatment.  
DVH-based treatment plan verification is a universal methodology as it is 
implementable for any radiotherapy treatment technique in any treatment site. In 
addition, DVH-based action levels are easily adapted and therefore suitable for patient 
specific QA. Furthermore, to minimise unjustified QA results, DVH-based action levels 
should differ from planning objectives to take into account minor systematic dose 
differences between the TPS and QA-system. Therefore, DVH-based action levels have to 
be set with care. For this study, the DVH-based action levels were based on a consensus of 
the radiation oncologist group based on their expert opinion combined with QUANTEC 
data [7], and found suitable for 3D dose verification. In order to minimise unjustified QA 
results, a re-evaluation of QA results based on a population analysis can be performed to 
tailor the action levels to the QA procedure for correct error-detection. 
 
Conclusion 
DVH-based treatment plan verification improves IMRT-QA as it increases insight in the 
uncertainty of dose deposition to patient specific structures allowing a treatment plan to 
be accepted or rejected based on clinically relevant dose differences. In addition, DVH-
based action levels clearly distinguish the role of the medical physicist and radiation 
oncologist within the QA-procedure. DVH-based treatment plan verification is a universal 
method suitable for patient specific QA applicable to any treatment site. Therefore we 
conclude that DVH-based treatment plan verification is complementary to gamma passing 
rates in verifying dosimetric accuracy improving head and neck IMRT-QA. 
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FOR INTENSITY MODULATEDRADIOTHERAPY 
(IMRT)
Chapter 7
Summarizing discussion and future perspectives
  Summarizing discussion 
In external beam radiotherapy the quality of the radiotherapy treatment plan (RT-
plan) is verified by patient specific quality assurance (QA) techniques such as pre-
treatment dose verification using dose calculations, direct dose measurements, or a 
combination of both. For a reliable dose verification this needs to be performed with a 
system independent of the treatment planning system (TPS). The dose verification system 
used for patient specific QA in this thesis, the COMPASS system (IBA Dosimetry), is capable 
of verifying in patient dose deposition based on dose calculations combined with or 
without measurements [1,2]. In these calculations the fluence is modelled based on the 
RT-plan and subsequently used for dose calculations in patient CT data. In case of a 
measurement based dose reconstruction, measurements are obtained with a detector 
array composed of ionization chambers (MatriXX Evolution, IBA Dosimetry). These 
measurements are used to correct, if needed, the modelled fluence used in patient dose 
calculations. 
For measurement based dose verification, the detector resolution is an important 
limitation due to the relatively large detector spacing of 7.62 mm [3]. In relation to high 
resolution dose reconstructions (e.g. 2 x 2 x 2 mm3), the low resolution detector does not 
meet the Nyquist sampling theorem which can result in incorrect dose reconstructions. To 
partly overcome the low resolution limitation of the detector array, a (low resolution) 
correction kernel has been introduced in the COMPASS system which corrects the 
modelled (high resolution) fluence in case of a difference in expected and measured 
detector response [1]. The limitations of the correction kernel method were evaluated in 
chapter 2. Results revealed that the use of the correction kernel allowed the system to 
successfully detect dose differences caused by multi leaf collimator (MLC) leaf positioning 
errors but that this kernel also introduced dose reconstruction artefacts resulting in 
overestimation and blurring of observed dose differences. In literature, alternative 
approaches were introduced to overcome limitations caused by the resolution of the 
detector by performing a detector shift [4]. For this thesis a different approach was 
introduced in chapter 3 using an iterative reconstruction method for a MLC consisting of 1 
cm leafs. The iterative reconstruction method used a fluence model, detector model and 
an optimizer to reconstruct MLC leaf positions based on measurements. Reconstructed 
MLC leaf positions were for reconstruction purposes implemented in the original RT plan 
for a better representation of the MLC leaf positions during treatment. Implementation of 
reconstructed MLC leaf positions minimized the need for the correction kernel, and 
therefore reduced dose reconstruction artefacts. Nevertheless, for a high resolution MLC 
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system the resolution of the detector showed to be inadequate. This was illustrated in 
chapter 4 where a high resolution MLC with 5 mm leafs was used for dose reconstruction. 
The measurement setup allowed one row of ionization chambers to be affected by two 
neighbouring leafs with a dose reconstruction error as a result. The iterative 
reconstruction method was unable to distinguish between the contribution of a single leaf 
and a neighbouring leaf. To overcome the dose reconstruction error, MLC leaf position 
reconstruction was performed for even and uneven MLC leafs independently; i.e. by the 
use of a ‘shutter technique’. In chapter 4 promising results were obtained as MLC leaf 
positions were reconstructed with sub-millimetre accuracy for a high resolution MLC. 
However, minor MLC leaf position errors still remained. These errors resulted in a 
difference between modelled and measured detector response which was then corrected 
for by the correction kernel method introducing minor dose reconstruction artefacts. As 
an alternative to the iterative reconstruction method, information on MLC leaf positions 
could also be obtained using log file information [5,6] or other detector systems such as a 
flat multi-wire transmission-type ionization chamber [7] or an electronic imaging device 
(EPID) [8]. These could be of interest in determining high resolution MLC leaf positions 
needed for in vivo dose verification purposes. Other measurement based pre-treatment 
dose verification systems using detectors composed of ionization chambers have been 
described in literature [9–11], but are also limited by their resolution. As an alternative, 
EPID dosimetry has shown to be a powerful tool for accurate high resolution in vivo 
dosimetry [12,13].  
Pre-treatment dose verification based on measurements is time consuming. With the 
increase in the number of radiotherapy treatments combined with the limited 
departmental resources, an efficient dose verification procedure is needed without 
compromising patient treatment quality. A tempting solution for efficient dose verification 
is to switch from measurement based to calculation based pre-treatment dose verification 
as research has shown that for the vast majority of treatment plans (>99.5%) no dose 
delivery errors occur when routine patient specific QA is performed [14]. As a 
consequence, verification of data transfer to the linear accelerator and treatment delivery 
will then be excluded. To reduce this risk, dose calculations could be combined with 
measurements. In chapter 5 a methodology allowing efficient and reliable dose 
verification was presented; i.e. the hybrid-QA methodology. The hybrid-QA methodology 
underlined the possibility of performing efficient pre-treatment dose verification by 
including measurements for only a selection of treatment plans. Because the MatriXX 
detector was mounted on the treatment machine, the hybrid-QA methodology in 
combination with the MatriXX detector is not compatible with on-line dose measurements 
necessary for dose verification based on actual treatment delivery (on-line dose 
verification). The described implementation of hybrid-QA in chapter 5 would therefore 
gain substantial practical value when including detector systems suitable for on-line dose 
verification techniques. Research has shown newly developed detector types suitable for 
the COMPASS system and online dose verification [15,16]. The hybrid-QA is furthermore a 
universal method for 3D dose verification as it can be combined with various dose 
verification tools and/or treatment techniques. In particular for proton therapy the hybrid-
QA can be of interest as dose verification for proton treatments using measurements is 
time consuming resulting in a serious bottleneck in treatment efficiency. 
In current practice, dose differences are generally evaluated by physicists using 
various dose evaluation parameters derived from the gamma analysis which is difficult to 
extrapolate to clinical implications [17]. This is underlined by research which shows a weak 
correlation between gamma passing rates and dose volume histogram (DVH) criteria [18–
20]. To overcome the limitations of the widely implemented gamma evaluation, an 
alternative approach was introduced in Chapter 6 in which pre-treatment dose 
verification was performed using DVH-based criteria in addition to gamma passing rates. 
Although almost no treatment plans failed clinical acceptance criteria (0.3%), the failed 
treatment plans were detected by DVH-based criteria and missed by gamma passing rates. 
The introduction of DVH criteria furthermore allows the dose verification procedure to be 
tailored to individual patients as patient specific DVH-criteria can be introduced and 
applied. Nevertheless, it has to be noted that DVH-based dose verification is limited as 
well as it lacks spatial information. This can result in large dose differences within a 
delineated structure to go undetected [21]. In addition, as only delineated structures are 
evaluated in DVH-based dose verification, clinically relevant dose differences outside 
delineated structures can be missed. Therefore, it is advised to combine DVH criteria with 
gamma passing rates for a more complete pre-treatment dose verification. It furthermore 
has to be pointed out that DVH-criteria in itself as described in chapter 6 may include 
some arbitrariness. This can be further improved when DVH-criteria are based on an 
overarching hospital based consensus of radiation oncologist groups expert opinion 
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As described in the introduction, the research presented in this thesis represents only 
a part of the entire external beam radiotherapy treatment procedure. In terms of pre-
treatment dose verification, this thesis focussed mainly on uncertainties which can occur 
in the TPS and the linear accelerator (linac). Accuracy of the TPS is verified by calculation 
based dose verifications and treatment delivery by the linac is verified using measurement 
based dose reconstructions. For the entire treatment procedure many uncertainties still 
remain however. In particular inter-fractional and intra-fractional anatomical 
deformations can result in discrepancies between patient geometry obtained for pre-
treatment purposes and actual patient geometry during treatment [23]. Research has 
shown that patient geometry changes can result in unwanted target underdosage and/or 
OAR overdosage [24,25].  
Information on actual patient geometry can be obtained by including additional 
imaging techniques such as cone-beam-CT (CBCT) and repeat-CT data. Inclusion of 
additional imaging enables quantification of inter-fractional and intra-fractional patient 
geometry changes during the entire external beam radiotherapy treatment. This 
information can then be used for day by day treatment decision purposes allowing 
adaptive radiotherapy (ART) [26]. The introduction of ART in daily clinical practice 
consequently affects the dose verification procedure. Furthermore, due to the inclusion of 
additional imaging, patient specific QA is shifting from offline to online dose verification. 
Inter- and intra-fractional patient geometry changes 
Inter- and intra- fractional patient geometry changes can partially be accounted for in 
the planning process by performing robust treatment planning [27,28]. Even so, in robust 
treatment planning, assumptions are made on expected patient geometry changes based 
on systematic and random setup errors [29], and motion probability distributions [27] 
which may deviate from the actual geometry during treatment. 
Inter-fractional patient geometry changes caused by patient deformations and/or 
organ filling can occur throughout the entire treatment resulting in a varying patient 
geometry for each individual fraction. Inter-fractional patient geometry changes caused by 
organ filling can be accounted for during the treatment planning process by creating a set 
of treatment plans for various organ filling. During day to day treatment, CBCT data may 
then be used to quantify the organ filling of the day and to select the treatment plan 
which corresponds best with the current patient geometry [30,31]. In terms of dose 
verification, the dataset of treatment plans for various organ filling can be verified prior to
treatment delivery by calculation based dose calculations. Even though the plan of the day
will in comparison to the planning CT correspond better to the actual patient geometry, 
there will remain discrepancies between the patient geometry used for the plan of the day
and the actual patient geometry obtained with a CBCT. For a dose verification based on
the actual patient geometry, dose verification using CBCT data is therefore of interest. This
is challenging as obtained images suffer, in comparison to the planning CT, from an
increase in radiation scatter, and therefore cannot be simply converted to electron
densities needed for dose calculations [32,33]. Dose verification using CBCT data is already
under development [34–37], and is expected to become part of the daily dose verification
routine for external beam radiotherapy.
To guarantee treatment outcome and patient safety, unwanted target underdosage
and/or OAR overdosage caused by inter-fractional patient geometry changes need to be
monitored and taken into account for each fraction throughout the entire radiotherapy
treatment procedure. This can be achieved by accumulating the delivered dose based on
the day by day patient geometry and day by day treatment delivery throughout the
treatment. By accumulating the delivered dose, decisions affecting the treatment can be
performed at each time point in the treatment procedure. In literature, digital image
registration (DIR) techniques have been described suitable for contour propagation and
dose accumulation for planning CT data and/or CBCT data [38–41]. DIR enables alignment
of image sets in a nonlinear way allowing a voxel based comparison of multiple scans. In
literature, various DIR techniques have been tested and showed varying registration
accuracy results for normal tissue and/or tumour tissue [42,43]. Due to the lack of a 
ground truth, the accuracy of a DIR system is difficult to determine. Therefore, clinical
decisions based on dose accumulation using DIR has to be performed with caution. As a 
solution a second DIR system independent of the clinical DIR system can be introduced to 
enhance correct interpretation of dose accumulation results.  
Unwanted intra-fractional patient geometry changes can occur by respiration and/or
heartbeat induced organ motion. During treatment planning, information on intra-
fractional patient geometry changes can be included by incorporating 4D-CT data [44–47].
For dose verification purposes, information on intra-fractional patient geometry changes
can be obtained and integrated using 4D-CBCT data [48–50].
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Online dose verification 
In comparison to offline pre-treatment dose verification, online dose verification 
allows a direct intervention of the treatment in case of erroneous dose delivery. In 
particular for treatments with high dose gradients in regions with significant movement, a 
direct intervention of treatment delivery can be of great importance. In literature a proof 
of concept has already been evaluated and proven sufficient for photon therapy in 
combination with EPID dosimetry and the planning CT [51]. For intra-fractional dose 
verification such concepts are of great interest to accurately verify the actual delivered 
dose to the patient for each individual fraction. 
A shift from offline pre-treatment dose verification to online day by day dose 
verifications based on actual patient geometry generates additional workload for the 
department. In addition, online dose verification needs to be performed on a minutes 
time scale while the patient is on the treatment table to minimize discomfort. This 
emphasizes the need for an efficient dose verification procedure even more. Efficiency can 
be improved by optimizing the work flow and minimizing human interaction. As stated by 
Olaciregui et. al., an ideal in vivo  dose verification program should (1) automatically 
decide which fractions need to be analysed for which treatments, (2) automatically gather 
treatment delivery data for these fractions, (3) automatically produce dosimetry reports, 
and (4) automatically raise alerts when deviations outside tolerance levels are detected 
[52]. Promising results were obtained as 95% of 3839 treatments were evaluated without 
human interventions substantially lowering the workload of pre-treatment dose 
verification procedure. Dose verification was performed on the planning CT and results 
revealed that part of the clinical non-relevant deviations originated from patient geometry 
changes. A more comprehensive online dose verification procedure is to be expected 




To guarantee patient treatment quality in external beam radiotherapy, high 
resolution 3D dose verification of the radiotherapy treatment plan is essential. High 
resolution 3D dose reconstruction can be performed using available low 2D resolution 
measurements. By combining calculation based dose calculations with measurement 
based dose reconstruction techniques, efficient and effective pre-treatment dose 
verification for target volumes and organs at risk can be performed. In addition, inclusion 
of DVH-based action levels improve insight in dose delivery to target volumes and organs 
at risk allowing patient individualized dose verification. With the introduction of additional 
imaging techniques, a shift from pre-treatment to day by day online in vivo dose 
verification using actual patient geometry is foreseen emphasizing the need for an 
efficient dose verification procedure. 
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and (4) automatically raise alerts when deviations outside tolerance levels are detected 
[52]. Promising results were obtained as 95% of 3839 treatments were evaluated without 
human interventions substantially lowering the workload of pre-treatment dose 
verification procedure. Dose verification was performed on the planning CT and results 
revealed that part of the clinical non-relevant deviations originated from patient geometry 
changes. A more comprehensive online dose verification procedure is to be expected 




To guarantee patient treatment quality in external beam radiotherapy, high 
resolution 3D dose verification of the radiotherapy treatment plan is essential. High 
resolution 3D dose reconstruction can be performed using available low 2D resolution 
measurements. By combining calculation based dose calculations with measurement 
based dose reconstruction techniques, efficient and effective pre-treatment dose 
verification for target volumes and organs at risk can be performed. In addition, inclusion 
of DVH-based action levels improve insight in dose delivery to target volumes and organs 
at risk allowing patient individualized dose verification. With the introduction of additional 
imaging techniques, a shift from pre-treatment to day by day online in vivo dose 
verification using actual patient geometry is foreseen emphasizing the need for an 
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  Nederlandse samenvatting 
Bij de behandeling van kanker door middel van radiotherapie wordt de patiënt 
bestraald met een hoog energetische stralenbundel. Door de tumor vanuit verschillende 
hoeken te bestralen wordt gezond omliggend weefsel gespaard waardoor de patiënt beter 
en sneller kan herstellen. Aan de hand van complexe bestralingsplannen is het mogelijk 
om met intensiteit gemoduleerde radiotherapie (IMRT) hoge dosis gradiënten te creëren. 
Deze hoge dosis gradiënten maakt het mogelijk kritieke organen te sparen met behoud 
van de vereiste tumordekking [1–3]. 
Om de kwaliteit van deze complexe bestralingsplannen te waarborgen wordt de door 
het treatment planning system (TPS) berekende dosisafgifte geverifieerd door een 
onafhankelijk dosisverificatie systeem. Dit kan aan de hand van driedimensionale (3D) 
dosisberekeningen, directe dosismetingen of een combinatie van beide. Ondanks de hoge 
kwaliteit van 3D dosisberekeningen kunnen er verschillen optreden tussen de dosisafgifte 
die berekend is door het TPS en de daadwerkelijke dosisafgifte door bijvoorbeeld 
afwijkingen in de posities van de multi-leaf-collimatoren (MLC). Om deze verschillen 
tijdig te achterhalen is het van belang informatie over de af te geven behandeling te 
integreren in de dosisverificatie procedure. Dit kan gerealiseerd worden door middel van 
directe dosismetingen gebruik makend van speciaal ontwikkelde sensoren en/of 
detectoren [4,5].  
Over het algemeen worden er twee type tweedimensionale (2D) detectoren gebruikt 
voor 3D dosisverificatie; de electronic portal imaging device (EPID) en 2D detectoren 
opgebouwd uit diodes of ionisatiekamers. De EPID detector werd geïntroduceerd ten 
behoeve van positieverificatie. Uitvoerig onderzoek heeft er vervolgens toe geleid dat de 
verkregen beelden van de EPID detector gebruikt kunnen worden voor het reconstrueren 
van de dosis [6]. Een groot voordeel van de EPID detector is de hoge resolutie en het feit 
dat de detector geïntegreerd is in de lineaire versneller. Dit maakt het mogelijk informatie 
over de dosisafgifte tijdens de behandeling te verzamelen. In tegenstelling tot een EPID 
detector worden 2D detectoren bestaande uit ionisatiekamers over het algemeen op de 
kop van de lineaire versneller of behandeltafel geplaatst zonder dat de patiënt op de 
behandeltafel ligt. Dit heeft als gevolg dat er geen informatie verzameld kan worden 
tijdens de daadwerkelijke behadeling [7–9]. Daarnaast is de resolutie van dit type 
detectoren beperkt. Daar tegenover staat dat onderzoek heeft aangetoond dat informatie 
verzameld met lage resolutie detectoren geschikt is voor het reconstrueren van hoge 
resolutie dosisverdelingen [10]. Door technologische ontwikkelingen van 2D detectoren 
opgebouwd uit ionisatiekamers wordt het ook mogelijk de dosis met dit type detector te 
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Nederlandse samenvatting 
Bij de behandeling van kanker door middel van radiotherapie wordt de patiënt 
bestraald met een hoog energetische stralenbundel. Door de tumor vanuit verschillende 
hoeken te bestralen wordt gezond omliggend weefsel gespaard waardoor de patiënt beter 
en sneller kan herstellen. Aan de hand van complexe bestralingsplannen is het mogelijk 
om met intensiteit gemoduleerde radiotherapie (IMRT) hoge dosis gradiënten te creëren. 
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dosisberekeningen, directe dosismetingen of een combinatie van beide. Ondanks de hoge 
kwaliteit van 3D dosisberekeningen kunnen er verschillen optreden tussen de dosisafgifte 
die berekend is door het TPS en de daadwerkelijke dosisafgifte door bijvoorbeeld 
afwijkingen in de posities van de multi-leaf-collimatoren (MLC). Om deze verschillen 
tijdig te achterhalen is het van belang informatie over de af te geven behandeling te 
integreren in de dosisverificatie procedure. Dit kan gerealiseerd worden door middel van 
directe dosismetingen gebruik makend van speciaal ontwikkelde sensoren en/of 
detectoren [4,5].  
Over het algemeen worden er twee type tweedimensionale (2D) detectoren gebruikt 
voor 3D dosisverificatie; de electronic portal imaging device (EPID) en 2D detectoren 
opgebouwd uit diodes of ionisatiekamers. De EPID detector werd geïntroduceerd ten 
behoeve van positieverificatie. Uitvoerig onderzoek heeft er vervolgens toe geleid dat de 
verkregen beelden van de EPID detector gebruikt kunnen worden voor het reconstrueren 
van de dosis [6]. Een groot voordeel van de EPID detector is de hoge resolutie en het feit 
dat de detector geïntegreerd is in de lineaire versneller. Dit maakt het mogelijk informatie 
over de dosisafgifte tijdens de behandeling te verzamelen. In tegenstelling tot een EPID 
detector worden 2D detectoren bestaande uit ionisatiekamers over het algemeen op de 
kop van de lineaire versneller of behandeltafel geplaatst zonder dat de patiënt op de 
behandeltafel ligt. Dit heeft als gevolg dat er geen informatie verzameld kan worden 
tijdens de daadwerkelijke behadeling [7–9]. Daarnaast is de resolutie van dit type 
detectoren beperkt. Daar tegenover staat dat onderzoek heeft aangetoond dat informatie 
verzameld met lage resolutie detectoren geschikt is voor het reconstrueren van hoge 
resolutie dosisverdelingen [10]. Door technologische ontwikkelingen van 2D detectoren 
opgebouwd uit ionisatiekamers wordt het ook mogelijk de dosis met dit type detector te 
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meten tijdens de daadwerkelijke behandeling van de patiënt op de behandeltafel [11]. 
Desalniettemin is het gebruik van detectoren voor het reconstrueren van de dosis een 
tijdrovende procedure. Door een toename in complexiteit en het aantal 
radiotherapeutische behandelingen is een efficiënte en effectieve dosisverificatie 
procedure van essentieel belang. 
Het dosisverificatie systeem beschreven in dit proefschrift maakt gebruik van een 
fluentie model, een detector model, een 3D dosisberekeningsmodule en een lage 
resolutie 2D detector bestaande uit 1020 ionisatie kamers [7]. Aan de hand van een 
bestralingsplan wordt de fluentie gemodelleerd. Deze fluentie kan direct als input gebruikt 
worden voor de 3D dosisberekeningsmodule. Indien er gebruik wordt gemaakt van een 2D 
meting wordt aan de hand van de berekende fluentie en het detector model een 
verwachte detector response berekend. Wanneer er verschillen optreden tussen de 
berekende en gemeten detector response wordt de berekende fluentie gecorrigeerd door 
middel van een correctie kernel. Afhankelijk van de grootte van de verschillen wordt de 
correctie kernel in meer of mindere mate toegepast. De gecorrigeerde fluentie wordt 
uiteindelijk gebruikt als input voor de 3D dosisberekeningsmodule voor het berekenen van 
de dosis op basis van de patiënt-CT. 
In hoofdstuk 2 van dit proefschrift is het effect van de correctie kernel op het 
reconstrueren van de dosis beschreven en geëvalueerd. Indien de kernel wordt toegepast, 
wordt de berekende dosis uitgesmeerd rond de positie waar het verschil tussen de 
berekende en gemeten detector respons optreedt. De gedetecteerde fout wordt daardoor 
enigszins overschat. Daarnaast verschilt het effect van de correctie kernel per positie in 
relatie tot de individuele ionisatie kamer. Met name op de rand van de ionisatie kamer 
wordt de gedetecteerde fout overschat. Desalniettemin worden verschillen tussen het TPS 
en het daadwerkelijke bestralingsplan als gevolg van een MLC verschuiving voldoende 
gedetecteerd ten behoeve van de dosisverificatie van IMRT bestralingsplannen.  
In hoofdstuk 3 is een alternatieve methode geïntroduceerd en geëvalueerd om het 
effect van de kernel zoals beschreven in hoofdstuk 2 te verminderen. Door middel van een 
iteratieve reconstructie methode zijn nog voor de daadwerkelijke dosisberekening de 
posities van de MLC gereconstrueerd aan de hand van een 2D meting. De meetopstelling 
was zodoende dat één rij ionisatiekamers van de detector afgedekt konden worden door 
één MLC paar. Het reconstrueren van de MLC posities heeft als gevolg dat de verwachte 
en gemeten detector response weinig tot geen verschillen vertonen waardoor de kernel in 
mindere mate toegepast wordt en de gedetecteerde fout minder wordt overschat. 
Posities van individuele MLC-leafs waren met hoge precisie te reconstrueren, 
onafhankelijk van de grootte van de fout, de positie van de fout in relatie tot de ionisatie 
kamer en het aantal monitor eenheden. Dit gold echter alleen voor de beschreven 
meetopstelling. 
De beschreven methode in hoofdstuk 3 was beperkt door de meetopstelling. 
Wanneer één rij ionisatiekamers van de detector werd afgedekt door meer dan één MLC 
paar kon de iteratieve reconstructie methode geen onderscheid maken tussen de 
verschillende MLC-leafs. Een aanvulling op de methode beschreven in hoofdstuk 3 is 
beschreven en geëvalueerd in hoofdstuk 4. Het bestralingsplan werd zodoende aangepast 
dat er twee extra metingen werden verzameld. Naast de originele meting van het 
reguliere bestralingsplan werd er één meting met alle even MLC-leafs gesloten en één 
meting met alle oneven MLC-leafs gesloten. Zodoende kon de iteratieve reconstructie 
methode voor de twee extra metingen wel onderscheid maken tussen de bijdrage van de 
even en oneven MLC-leafs. Door deze aanpassing was het mogelijk de positie van 
individuele MLC-leafs met hoge precisie te bepalen. De gereconstrueerde posities werden 
ten slotte gebruikt voor het verifiëren van de dosis voor het reguliere bestralingsplan.  
Door de toename in complexiteit van de bestralingsplannen wordt de kans op het 
ontstaan van fouten vergroot. Om deze fouten tijdig te detecteren is het van belang het 
effect van de lineaire versneller te integreren in de dosisverificatie procedure. Dit kan 
gerealiseerd worden door het reconstrueren van de dosis gebruik makend van directe 
dosismetingen. Dit is echter een tijdrovende procedure en door de toename van het 
aantal bestralingsplannen is een efficiënte en betrouwbare dosisverificatie procedure van 
essentieel belang. In hoofdstuk 5 van dit proefschrift is een methode ontwikkeld en 
geëvalueerd waarbij de snelheid van dosisberekeningen gecombineerd werd met de 
betrouwbaarheid van directe dosismetingen. Uit de resultaten bleek dat deze hybride 
aanpak het mogelijk maakte grote hoeveelheden complexe bestralingsplannen efficiënt en 
effectief te verifiëren. 
Geobserveerde dosisverschillen worden over het algemeen in kaart gebracht met een 
methodiek die absolute dosisverschillen combineert met een verschuiving van de dosis; de 
gamma index. In vergelijking met een dosis volume histogram (DVH) is de gamma index 
moeilijk te vertalen naar klinische relevantie. In hoofdstuk 6 van dit proefschrift is de 
meerwaarde van dosisverificatie criteria op basis van DVH informatie onderzocht. De 
combinatie van DVH criteria en de gamma index verhoogde inzicht in de geobserveerde 
dosisverschillen tussen het TPS en het onafhankelijk dosisverificatie systeem binnen de 
IMRT dosisverificatie procedure. Daarnaast werd het mogelijk in samenwerking met de 
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Desalniettemin is het gebruik van detectoren voor het reconstrueren van de dosis een
tijdrovende procedure. Door een toename in complexiteit en het aantal
radiotherapeutische behandelingen is een efficiënte en effectieve dosisverificatie 
procedure van essentieel belang.
Het dosisverificatie systeem beschreven in dit proefschrift maakt gebruik van een
fluentie model, een detector model, een 3D dosisberekeningsmodule en een lage 
resolutie 2D detector bestaande uit 1020 ionisatie kamers [7]. Aan de hand van een
bestralingsplan wordt de fluentie gemodelleerd. Deze fluentie kan direct als input gebruikt
worden voor de 3D dosisberekeningsmodule. Indien er gebruik wordt gemaakt van een 2D 
meting wordt aan de hand van de berekende fluentie en het detector model een
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berekende en gemeten detector response wordt de berekende fluentie gecorrigeerd door 
middel van een correctie kernel. Afhankelijk van de grootte van de verschillen wordt de
correctie kernel in meer of mindere mate toegepast. De gecorrigeerde fluentie wordt 
uiteindelijk gebruikt als input voor de 3D dosisberekeningsmodule voor het berekenen van 
de dosis op basis van de patiënt-CT.
In hoofdstuk 2 van dit proefschrift is het effect van de correctie kernel op het
reconstrueren van de dosis beschreven en geëvalueerd. Indien de kernel wordt toegepast,
wordt de berekende dosis uitgesmeerd rond de positie waar het verschil tussen de 
berekende en gemeten detector respons optreedt. De gedetecteerde fout wordt daardoor
enigszins overschat. Daarnaast verschilt het effect van de correctie kernel per positie in 
relatie tot de individuele ionisatie kamer. Met name op de rand van de ionisatie kamer 
wordt de gedetecteerde fout overschat. Desalniettemin worden verschillen tussen het TPS
en het daadwerkelijke bestralingsplan als gevolg van een MLC verschuiving voldoende
gedetecteerd ten behoeve van de dosisverificatie van IMRT bestralingsplannen. 
In hoofdstuk 3 is een alternatieve methode geïntroduceerd en geëvalueerd om het
effect van de kernel zoals beschreven in hoofdstuk 2 te verminderen. Door middel van een
iteratieve reconstructie methode zijn nog voor de daadwerkelijke dosisberekening de
posities van de MLC gereconstrueerd aan de hand van een 2D meting. De meetopstelling
was zodoende dat één rij ionisatiekamers van de detector afgedekt konden worden door 
één MLC paar. Het reconstrueren van de MLC posities heeft als gevolg dat de verwachte 
en gemeten detector response weinig tot geen verschillen vertonen waardoor de kernel in
mindere mate toegepast wordt en de gedetecteerde fout minder wordt overschat.
Posities van individuele MLC-leafs waren met hoge precisie te reconstrueren, 
onafhankelijk van de grootte van de fout, de positie van de fout in relatie tot de ionisatie
kamer en het aantal monitor eenheden. Dit gold echter alleen voor de beschreven 
meetopstelling. 
De beschreven methode in hoofdstuk 3 was beperkt door de meetopstelling. 
Wanneer één rij ionisatiekamers van de detector werd afgedekt door meer dan één MLC 
paar kon de iteratieve reconstructie methode geen onderscheid maken tussen de 
verschillende MLC-leafs. Een aanvulling op de methode beschreven in hoofdstuk 3 is 
beschreven en geëvalueerd in hoofdstuk 4. Het bestralingsplan werd zodoende aangepast 
dat er twee extra metingen werden verzameld. Naast de originele meting van het 
reguliere bestralingsplan werd er één meting met alle even MLC-leafs gesloten en één 
meting met alle oneven MLC-leafs gesloten. Zodoende kon de iteratieve reconstructie 
methode voor de twee extra metingen wel onderscheid maken tussen de bijdrage van de 
even en oneven MLC-leafs. Door deze aanpassing was het mogelijk de positie van 
individuele MLC-leafs met hoge precisie te bepalen. De gereconstrueerde posities werden 
ten slotte gebruikt voor het verifiëren van de dosis voor het reguliere bestralingsplan.  
Door de toename in complexiteit van de bestralingsplannen wordt de kans op het 
ontstaan van fouten vergroot. Om deze fouten tijdig te detecteren is het van belang het 
effect van de lineaire versneller te integreren in de dosisverificatie procedure. Dit kan 
gerealiseerd worden door het reconstrueren van de dosis gebruik makend van directe 
dosismetingen. Dit is echter een tijdrovende procedure en door de toename van het 
aantal bestralingsplannen is een efficiënte en betrouwbare dosisverificatie procedure van 
essentieel belang. In hoofdstuk 5 van dit proefschrift is een methode ontwikkeld en 
geëvalueerd waarbij de snelheid van dosisberekeningen gecombineerd werd met de 
betrouwbaarheid van directe dosismetingen. Uit de resultaten bleek dat deze hybride 
aanpak het mogelijk maakte grote hoeveelheden complexe bestralingsplannen efficiënt en 
effectief te verifiëren. 
Geobserveerde dosisverschillen worden over het algemeen in kaart gebracht met een 
methodiek die absolute dosisverschillen combineert met een verschuiving van de dosis; de 
gamma index. In vergelijking met een dosis volume histogram (DVH) is de gamma index 
moeilijk te vertalen naar klinische relevantie. In hoofdstuk 6 van dit proefschrift is de 
meerwaarde van dosisverificatie criteria op basis van DVH informatie onderzocht. De 
combinatie van DVH criteria en de gamma index verhoogde inzicht in de geobserveerde 
dosisverschillen tussen het TPS en het onafhankelijk dosisverificatie systeem binnen de 
IMRT dosisverificatie procedure. Daarnaast werd het mogelijk in samenwerking met de 
radiotherapeut dosisverificatie criteria af te stemmen op de individuele patiënt. 
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Om de kwaliteit van complexe bestralingsplannen te waarborgen is een hoogwaardige 
3D dosisverificatie procedure van essentieel belang. Het onderzoek beschreven in  
dit proefschrift heeft aangetoond dat lage resolutie 2D detectoren geschikt zijn voor het 
nauwkeurig reconstrueren van hoge resolutie 3D dosis. Het combineren van dosis 
berekeningen met directe dosismetingen maakt het mogelijk grote hoeveelheden 
complexe bestralingsplannen efficiënt en effectief te controleren. Daarnaast wordt het 
mogelijk een patiënt geïndividualiseerde dosisverificatie uit te voeren door DVH-criteria 
toe te voegen aan de dosisverificatie procedure wat de kwaliteit van de behandeling ten 
goede komt.  
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